

Tuesday, June 05, 2018

Volume 34 No. 6



NOTICE – Items in this issue will be listed online weekly and printed monthly.

### NAME CHANGES

(For details on individual listings, see the News Section of this issue)

Bingham Canyon Corp (to PCT Ltd)  
GVCL Ventures Inc (to Rain Forest International Inc)

### AC PARTNERS INC

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Total revenues	213,254	119,955
Cost & expenses	156,046	105,779
Operating income	57,208	14,176
Net before taxes	57,208	14,176
Income taxes	17,503	4,654
<b>Net income</b>	<b>39,705</b>	<b>9,522</b>

Earnings common share

Primary	\$0.00	\$0.01
Fully Diluted	\$0.00	\$0.01

Common Shares:

Full Diluted	51,648,148	1,643,148
Year-end	51,643,847	1,643,148

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
<b>Assets:</b>		
Cash & equivalents	95,876	
Inventories	19,360	
Current assets	115,236	
Net property & equip.	14,479	
Total assets	136,076	
<b>Liabilities:</b>		
Current liabilities	64,795	
Stockholders' equity	83,251	
Net current assets	50,441	

### ACACIA DIVERSIFIED HOLDINGS INC

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Total revenues	91,914	147,646
Cost & expenses	512,561	607,296
Operating income	(421,263)	(461,361)
Other income (expense), net		1,000
Net before taxes	(432,790)	(694,511)
<b>Net income</b>	<b>(432,790)</b>	<b>(694,511)</b>

Earnings common share

Primary	\$(0.02)	\$(0.04)
Fully Diluted	\$(0.02)	\$(0.04)

Common Shares:

Full Diluted	17,818,766	17,086,228
Year-end	18,093,000	17,329,462

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
<b>Assets:</b>		
Cash & equivalents	26,470	
Inventories	54,462	
Current assets	93,203	
Net property & equip.	466,994	
Total assets	563,538	
<b>Liabilities:</b>		
Current liabilities	1,195,174	
Stockholders' equity	(631,636)	
Net current assets	(1,101,971)	

### ACMAT CORP.

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Total revenues	976,128	1,151,220
Cost & expenses	783,158	924,749
Operating income	133,883	196,720
Net before taxes	133,883	196,720
Income taxes	35,027	32,752
<b>Net income</b>	<b>98,856</b>	<b>163,968</b>

Earnings common share

Primary	\$0.12	\$0.19
Common Shares:		
Year-end	828,800	866,295

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
<b>Assets:</b>		
Cash & equivalents	1,590,807	
Current assets	6,114,042	
Net property & equip.	4,656,998	
Total assets	63,592,433	
<b>Liabilities:</b>		
Current liabilities	15,289,319	
Long-term debt	4,717,643	
Stockholders' equity	29,096,969	
Net current assets	(9,175,277)	

### ADMIRAL FINANCIAL CORP.

Earnings, 9 mos. to Mar 31(Consol. – \$):

	2018	2017
Earnings common share		
Common Shares:		
Year-end	10,985,046	10,985,046

### ADVANCED OXYGEN TECHNOLOGIES, INC.

Earnings, 9 mos. to Mar 31(Consol. – \$):

	2018	2017
Total revenues	29,849	26,792
Cost & expenses	15,893	19,808
Operating income	13,956	6,984
Interest expense	4,550	5,027
Net before taxes	9,406	1,957
Income taxes	5,380	4,298
<b>Net income</b>	<b>4,026</b>	<b>(2,341)</b>

Earnings common share

Primary	\$0.00	\$(0.00)
Fully Diluted	\$0.00	\$(0.00)

Common Shares:

Full Diluted	2,302,945	2,292,945
Year-end	2,292,945	2,292,945

### AGENT INFORMATION SOFTWARE INC

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Net Sales	1,245,841	1,240,559
Cost & expenses	1,179,901	1,147,700
Operating income	65,940	92,859
Other income (expense), net	732	396
Net before taxes	66,672	93,255
Income taxes	14,998	(21,000)
<b>Net income</b>	<b>51,674</b>	<b>114,255</b>

Earnings common share

Primary	\$0.01	\$0.03
Fully Diluted	\$0.01	\$0.02

Common Shares:

Full Diluted	5,061,243	4,857,827
Year-end	4,270,910	4,269,610

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
<b>Assets:</b>		
Cash & equivalents	1,406,012	
Current assets	1,630,564	
Net property & equip.	2,692,888	
Total assets	4,323,452	
<b>Liabilities:</b>		
Current liabilities	1,635,085	
Long-term debt	10,897	
Stockholders' equity	2,525,470	
Net current assets	(4,521)	

### AGENUS INC

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Total revenues	1,636,041	26,955,843
Cost & expenses	43,384,844	40,213,499
Operating income	(41,748,803)	(13,257,656)
Interest expense	2,780,890	4,585,657
Other income (expense), net	(9,731,450)	740,134
<b>Net income</b>	<b>(54,261,143)</b>	<b>(17,103,179)</b>

Balance for common

Earnings common share

Primary	\$(0.53)	\$(0.18)
Fully Diluted	\$(0.53)	\$(0.18)

Common Shares:

Full Diluted	102,576,334	93,508,120
Year-end	103,280,951	98,702,552

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
<b>Assets:</b>		
Cash & equivalents	52,347,634	
Inventories	62,241	
Current assets	65,193,078	
Net property & equip.	27,035,584	
Total assets	130,815,696	
<b>Liabilities:</b>		
Current liabilities	30,162,157	
Long-term debt	12,766,000	
Stockholders' equity	(113,233,591)	
Net current assets	35,030,921	

### ALADDIN INTERNATIONAL INC

Earnings, 9 mos. to Mar 31(Consol. – \$):

	2018	2017
Cost & expenses	60,944	41,951
Operating income	(60,944)	(41,951)
<b>Net income</b>	<b>(60,941)</b>	<b>(53,033)</b>

Earnings common share

Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)

Common Shares:

Full Diluted	4,548,435	4,548,435
Year-end	7,180,199	4,548,435

### ALBIREO PHARMA INC

Earnings, 3 mos. to Mar 31(Consol. – \$000):

	2018	2017
Total revenues	11,202	1
Cost & expenses	11,783	6,098
Operating income	(581)	(6,097)
Other income (expense), net	(22)	(325)
Net before taxes	(1,619)	(6,671)
<b>Net income</b>	<b>(1,619)</b>	<b>(6,671)</b>

Earnings common share

Primary	\$(0.15)	\$(1.06)
Fully Diluted	\$(0.15)	\$(1.06)

Common Shares:

Full Diluted	10,897	6,293
Year-end	11,897	6,293

**Consolidated Balance Sheet Items, as of (\$000):**

	2018	2017
<b>Assets:</b>		
Cash & equivalents	192,916	
Current assets	195,015	
Net property & equip.	172	
Total assets	212,896	
<b>Liabilities:</b>		
Current liabilities	7,156	
Stockholders' equity	160,166	
Net current assets	187,859	

### ALPHA NETWORK ALLIANCE VENTURES INC

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Total revenues	33,048	3,492
Cost & expenses	219,254	132,047
<b>Net income</b>	(186,206)	(128,555)
Earnings common share		
Primary	\$(0.01)	\$
Common Shares:		
Year-end	113,405,751	113,405,751

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	6,560
Current assets	81,165
Net property & equip.	8,516
Total assets	89,681
Liabilities:	
Current liabilities	2,367,154
Stockholders' equity	(2,277,473)
Net current assets	(2,285,989)

**AMARILLO BIOSCIENCES INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	56,590	
Cost & expenses	242,648	185,013
Operating income	(186,058)	(185,013)
Interest expense	1,380	3,959
<b>Net income</b>	(187,438)	(188,972)
Balance for common	(192,430)	
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	33,243,580	22,277,261
Year-end	33,724,261	22,350,935

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	1,706,804
Current assets	1,719,380
Net property & equip.	22,693
Total assets	1,920,330
Liabilities:	
Current liabilities	1,140,237
Stockholders' equity	698,927
Net current assets	579,143

**AMERICAN ENERGY GROUP LTD.****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	572,283	499,269
Operating income	(572,621)	(499,651)
Other income (expense), net	(76,514)	(258,183)
Net before taxes	(723,797)	(840,695)
<b>Net income</b>	(723,797)	(840,695)
Earnings common share		
Primary	\$(0.01)	\$
Fully Diluted	\$(0.01)	\$
Common Shares:		
Full Diluted	71,047,930	66,823,854
Year-end	72,832,862	67,975,719

**ANTARES PHARMA INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	12,703,000	12,007,000
Cost & expenses	18,322,000	16,773,000
Operating income	(5,619,000)	(4,766,000)
Other income (expense), net	57,000	30,000
<b>Net income</b>	(6,193,000)	(4,736,000)
Earnings common share		
Primary	\$(0.04)	\$(0.03)
Fully Diluted	\$(0.04)	\$(0.03)
Common Shares:		
Full Diluted	156,724,000	155,215,040
Year-end	156,821,000	155,447,871

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	23,111,000
Inventories	9,929,000
Current assets	53,037,000
Net property & equip.	15,892,000
Total assets	71,439,000
Liabilities:	
Current liabilities	18,067,000

Long-term debt	24,925,000
Stockholders' equity	28,247,000
Net current assets	34,970,000

**APPLIED MINERALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	45,647	795,282
Cost & expenses	1,426,593	2,017,019
Operating income	(1,704,090)	(1,552,522)
Other income (expense), net	(7,829,841)	897,276
<b>Net income</b>	(12,075,982)	(2,728,440)
Earnings common share		
Primary	\$(0.08)	\$(0.03)
Fully Diluted	\$(0.08)	\$(0.03)
Common Shares:		
Full Diluted	145,620,493	108,613,549
Year-end	150,388,549	108,613,549

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	72,167
Current assets	239,639
Net property & equip.	2,479,247
Total assets	2,935,749
Liabilities:	
Current liabilities	1,407,296
Long-term debt	35,520,026
Stockholders' equity	(44,218,764)
Net current assets	(1,167,657)

**APPYEA INC.****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	12,843	719
Cost & expenses	494,768	283,451
Operating income	(507,169)	(315,524)
Interest expense	324,496	16,495
Other income (expense), net	(509,568)	4,216
<b>Net income</b>	(1,341,233)	(327,803)
Earnings common share		
Common Shares:		
Full Diluted	913,338,132	464,667,527
Year-end	1,168,413,424	464,667,527

**ARCA BIOPHARMA, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	2,773,000	4,381,000
Operating income	(2,773,000)	(4,381,000)
<b>Net income</b>	(2,735,000)	(4,338,000)
Earnings common share		
Primary	\$(0.20)	\$(0.48)
Fully Diluted	\$(0.20)	\$(0.48)
Common Shares:		
Full Diluted	13,620,710	9,094,276
Year-end	13,914,320	9,172,868

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	12,096,000
Current assets	12,727,000
Net property & equip.	37,000
Total assets	12,788,000
Liabilities:	
Current liabilities	1,719,000
Stockholders' equity	11,054,000
Net current assets	11,008,000

**ARKOSE ENERGY CORP**

**Stock Split Announcement** On May 24, 2018, Co. effected 1-for-90 reverse split.

**ARTISTMSS INTERNATIONAL GROUP INC**

**Name Change Development** On May 21, 2018, Co. announced that it intends to effectuate, subject to approval by the Financial Industry Regulatory Authority (FINRA), a corporate action to change its name to RCoin Holdings, Inc.

**ASAP EXPO INC**

**Name Change Development** On May 3, 2018, Co. announced that it intends to change its name to GreenBox Pos LLC.

**ASIA PACIFIC BOILER CORP**

**New Accountant** On May 21, 2018, Co. dismissed Anton & Chia, LLP and engaged HKCMCPA Company Limited as its new independent public accounting firm.

**ASSEMBLY BIOSCIENCES INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	20,237,209	14,614,198
Operating income	(16,672,149)	(13,929,829)
Interest income	446,406	136,484
Invest. income	(23,016)	(137,248)
<b>Net income</b>	(16,248,759)	(13,930,593)
Earnings common share		
Primary	\$(0.80)	\$(0.81)
Fully Diluted	\$(0.80)	\$(0.81)
Common Shares:		
Full Diluted	20,231,804	17,268,280
Year-end	20,386,736	17,318,044

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	66,926,630
Current assets	113,225,600
Net property & equip.	731,500
Total assets	156,020,828
Liabilities:	
Current liabilities	12,179,933
Stockholders' equity	102,381,249
Net current assets	101,045,667

**ASV HOLDINGS INC**

**New Accountant** On May 18, 2018, Co. dismissed UHY LLPB and engaged DO USA, LLP as its new independent public accounting firm.

**ATHERSYS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues	1,066	1,470
Cost & expenses	11,142	7,704
Operating income	(10,262)	(6,398)
Other income (expense), net	107	767
<b>Net income</b>	(10,155)	(5,631)
Earnings common share		
Primary	\$(0.08)	\$(0.06)
Fully Diluted	\$(0.08)	\$(0.06)
Common Shares:		
Full Diluted	126,897	102,047
Year-end	137,959	111,317

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	49,673
Current assets	58,422
Net property & equip.	2,312
Total assets	60,934
Liabilities:	
Current liabilities	11,569
Stockholders' equity	47,532
Net current assets	46,853

**ATTIS INDUSTRIES INC**

**Resignation of Accountant** On June 4, 2018, Moss Adams LLP resigned as Co.'s independent public accounting firm.

**AZURRX BIOPHARMA INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	3,584,362	2,808,492
Operating income	(3,584,362)	(2,808,492)
Interest expense	48,635	874
Net before taxes	(3,632,997)	(2,809,366)
<b>Net income</b>	(3,632,997)	(2,809,366)
Earnings common share		
Primary	\$(0.29)	\$(0.29)
Fully Diluted	\$(0.29)	\$(0.29)
Common Shares:		
Full Diluted	12,447,438	9,631,088
Year-end	12,602,395	9,631,088

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	574,474
Current assets	1,805,945
Net property & equip.	148,777
Total assets	5,247,946
Liabilities:	
Current liabilities	2,819,450
Stockholders' equity	1,098,496
Net current assets	(1,013,505)

**BAGGER DAVE'S BURGER TAVERN INC****Earnings, 3 mos. to (Consol. - \$):**

	04/01/18	03/26/17
Total revenues	2,882,889	5,140,103
Cost & expenses	2,865,399	6,461,584
Operating income	(427,346)	(1,889,423)
Other income (expense), net	6,691	39,193
Net before taxes	(420,655)	(1,850,230)
Income taxes	2,759	
<b>Net income</b>	(423,413)	(1,850,230)
Earnings common share		
Primary	\$(0.02)	\$(0.07)
Fully Diluted	\$(0.02)	\$(0.07)
Common Shares:		
Full Diluted	27,266,528	26,692,119
Year-end	27,266,528	26,692,119

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	580,349	
Inventories	160,663	
Current assets	920,221	
Net property & equip.	8,900,807	
Total assets	10,330,205	
Liabilities:		
Current liabilities	1,396,406	
Stockholders' equity	8,097,502	
Net current assets	(476,185)	

**BALANCE LABS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	500	
Cost & expenses	152,597	145,216
Operating income	(152,597)	(144,716)
Interest expense	29,669	171,241
Gains or losses	265,000	
<b>Net income</b>	82,734	(315,957)
Earnings common share		
Primary	\$(0.01)	
Fully Diluted	\$(0.01)	
Common Shares:		
Full Diluted	24,574,761	21,620,000
Year-end	21,620,000	21,620,000

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	72,451	
Current assets	101,776	
Net property & equip.	5,399	
Total assets	452,175	
Liabilities:		
Current liabilities	1,894,087	
Stockholders' equity	(1,441,912)	
Net current assets	(1,792,311)	

**BIOCEPT INC**

**Annual Meeting Development** On May 17, 2018, Co. announced that its Annual Meeting of Stockholders will be held on June 28, 2018, at 8:00 A.M., local time, at Co.'s offices, located at 5810 Nancy Ridge Drive, San Diego, California 92121.

**BIOCEPT INC**

**Stock Split Development** On May 17, 2018, Co. announced that at its Annual Meeting of Stockholders to be held on June 28, 2018, Co. will be asking its Stockholders to approve an amendment to Co.'s Certificate of Amendment of Certificate of Incorporation to effect a reverse stock split of Co. common stock at a ratio in the range of 1:20 to 1:30, such ratio to be determined in the discretion of Co.'s board of directors.

**BIODELIVERY SCIENCES INTERNATIONAL INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	11,281,000	29,478,000
Cost & expenses	19,404,000	21,575,000
Operating income	(8,123,000)	7,903,000
Other income (expense), net	(7,000)	27,336,000
Net before taxes	(10,635,000)	32,353,000
Income taxes	74,000	(15,972,000)
<b>Net income</b>	(10,709,000)	48,325,000
Balance for common	(10,709,000)	48,325,000
Earnings common share		
Primary	\$(0.18)	\$0.89
Fully Diluted	\$(0.18)	\$0.87
Common Shares:		
Full Diluted	58,062,997	55,431,628
Year-end	58,631,031	55,325,972

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	12,090,000	
Inventories	5,441,000	
Current assets	28,482,000	
Net property & equip.	3,621,000	
Total assets	75,389,000	
Liabilities:		
Current liabilities	20,335,000	
Long-term debt	48,285,000	
Stockholders' equity	1,354,000	
Net current assets	8,147,000	

**BIOLASE INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	10,020,000	10,874,000
Cost & expenses	15,204,000	14,950,000
Operating income	(5,184,000)	(4,076,000)
Net before taxes	(4,989,000)	(4,068,000)
Income taxes	32,000	40,000
<b>Net income</b>	(5,021,000)	(4,108,000)
Earnings common share		
Primary	\$(0.05)	\$(0.06)
Fully Diluted	\$(0.05)	\$(0.06)
Common Shares:		
Full Diluted	102,347,000	67,583,000
Year-end	102,380,238	13,532,142

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	8,479,000	
Inventories	13,401,000	
Current assets	33,584,000	
Net property & equip.	3,424,000	
Total assets	40,384,000	
Liabilities:		
Current liabilities	13,132,000	
Long-term debt	1,934,000	
Stockholders' equity	24,937,000	
Net current assets	20,452,000	

**BIOSIG TECHNOLOGIES INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	2,634,216	2,895,945
Operating income	(2,637,119)	(2,899,014)
Other income (expense), net		(373,611)
Net before taxes	(2,637,034)	(3,272,625)
<b>Net income</b>	(2,637,034)	(3,272,625)
Balance for common	(2,942,080)	(3,296,370)
Earnings common share		
Primary	\$(0.09)	\$(0.14)
Fully Diluted	\$(0.09)	\$(0.14)
Common Shares:		
Full Diluted	29,944,445	23,051,872
Year-end	30,497,707	24,405,863

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	1,035,100	
Current assets	1,154,211	
Net property & equip.	19,457	
Total assets	1,196,145	
Liabilities:		
Current liabilities	821,447	
Stockholders' equity	(590,302)	
Net current assets	332,764	

**BLACKBOXSTOCKS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	143,295	127,612
Cost & expenses	337,976	316,969
Operating income	(197,795)	(191,351)
Interest expense	4,747	448
Net before taxes	(202,542)	(191,799)
<b>Net income</b>	(202,542)	(191,799)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	23,000,000	23,110,000
Year-end	23,000,000	23,110,000

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	26	
Inventories	22,294	
Current assets	40,643	
Net property & equip.	53,707	
Total assets	115,145	
Liabilities:		
Current liabilities	48,881	

	2018	2017
Assets:		
Cash & equivalents	78,022	
Current assets	322,346	
Net property & equip.	25,104	
Total assets	347,450	
Liabilities:		
Current liabilities	721,637	
Stockholders' equity	(374,187)	
Net current assets	(399,291)	

**BNET MEDIA GROUP INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	26,422	11,301
Operating income	(26,422)	(11,301)
<b>Net income</b>	(26,422)	(11,301)
Earnings common share		
Common Shares:		
Full Diluted	35,015,000	35,015,000
Year-end	35,015,000	35,015,000

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Liabilities:		
Current liabilities	273,568	
Stockholders' equity	(273,568)	
Net current assets	(273,568)	

**BOXLIGHT CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	5,996,685	4,194,429
Cost & expenses	7,778,005	5,636,334
Operating income	(1,781,320)	(1,441,905)
Interest expense	146,928	169,091
Other income (expense), net	(13,461)	49,646
Gains or losses	25,738	
<b>Net income</b>	(1,915,971)	(1,561,350)
Earnings common share		
Primary	\$(0.20)	\$(0.34)
Fully Diluted	\$(0.25)	\$(0.34)
Common Shares:		
Full Diluted	9,617,234	4,621,687
Year-end	9,648,197	4,621,687

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	448,345	
Inventories	3,738,723	
Current assets	8,498,731	
Net property & equip.	25,095	
Total assets	18,649,501	
Liabilities:		
Current liabilities	8,561,862	
Stockholders' equity	9,911,724	
Net current assets	(63,131)	

**BROADWIND ENERGY, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues	29,967	56,060
Cost & expenses	34,033	54,106
Operating income	(4,537)	1,603
Interest expense	298	139
Other income (expense), net	(3)	
Net before taxes	(4,838)	1,464
Income taxes	(27)	(5,018)
Income contin. oper.	(4,811)	6,482
Income discont. oper.	(27)	(155)
<b>Net income</b>	(4,838)	6,327
Earnings common share		
Primary	\$(0.32)	\$0.42
Fully Diluted	\$(0.32)	\$0.42
Common Shares:		
Full Diluted	15,257	15,195
Year-end	15,651	14,982

**Consolidated Balance Sheet Items, as of (\$000):**

	2018	2017
Assets:		
Cash & equivalents	26	
Inventories	22,294	
Current assets	40,643	
Net property & equip.	53,707	
Total assets	115,145	
Liabilities:		
Current liabilities	48,881	

Long-term debt	2,268
Stockholders' equity	61,663
Net current assets	(8,238)

**CAPRICOR THERAPEUTICS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total revenues	400,066	880,808
Cost & expenses	4,086,249	4,446,387
Operating income	(3,686,183)	(3,565,579)
Interest expense		105,320
Gains or losses	14,653	4,282
<b>Net income</b>	<b>(3,671,530)</b>	<b>(3,666,617)</b>
Earnings common share		
Primary	\$(0.14)	\$(0.17)
Fully Diluted	\$(0.14)	\$(0.17)
Common Shares:		
Full Diluted	26,905,331	21,399,019
Year-end	27,970,879	21,399,019

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	7,169,262
Current assets	14,613,165
Net property & equip.	535,241
Total assets	15,388,422
Liabilities:	
Current liabilities	1,477,899
Stockholders' equity	10,534,264
Net current assets	13,135,266

**CARDINAL ETHANOL LLC**

Earnings, 6 mos. to Mar 31(Consol. - \$):

	2018	2017
Total revenues	121,567,824	117,528,266
Cost & expenses	118,349,737	107,089,799
Operating income	3,218,087	10,438,467
Interest expense	425,493	270,467
Other income (expense), net	60,782	31,335
<b>Net income</b>	<b>2,853,376</b>	<b>10,199,335</b>
Earnings common share		
Primary	\$195.00	\$698.00
Fully Diluted	\$195.00	\$698.00
Common Shares:		
Full Diluted	14,606	14,606
Year-end	14,606	

**CASI PHARMACEUTICALS, INC.**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	3,687,352	1,693,450
Interest income	8,781	
Other income (expense), net	89,713	(6,874)
<b>Net income</b>	<b>(3,590,910)</b>	<b>(1,700,182)</b>
Earnings common share		
Primary	\$(0.05)	\$(0.03)
Fully Diluted	\$(0.05)	\$(0.03)
Common Shares:		
Full Diluted	71,215,000	60,196,574
Year-end	79,641,876	60,196,574

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	49,887,600
Current assets	52,085,651
Net property & equip.	1,200,830
Total assets	71,162,019
Liabilities:	
Current liabilities	2,044,067
Long-term debt	1,498,931
Stockholders' equity	67,619,021
Net current assets	50,041,584

**CCUR HOLDINGS INC**

Earnings, 9 mos. to Mar 31(Consol. - \$000):

	2018	2017
Cost & expenses	6,510	5,156
Operating income	(6,510)	(5,156)
Interest income	371	48
Interest expense	4	
Other income (expense), net	(63)	(12)
Net before taxes	(6,206)	(5,120)
Income taxes	(1,140)	31
<b>Net income</b>	<b>17,785</b>	<b>(4,674)</b>
Earnings common share		
Primary	\$1.86	\$(0.51)

Fully Diluted	\$1.86	\$(0.51)
Common Shares:		
Full Diluted	9,549	9,232
Year-end	9,583	

**CELCUITY INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	2,076,308	993,911
Operating income	(2,076,308)	(993,911)
Interest income	108,361	6,561
Net before taxes	(1,967,947)	(987,350)
<b>Net income</b>	<b>(1,967,947)</b>	<b>(987,350)</b>
Earnings common share		
Primary	\$(0.19)	\$(0.15)
Fully Diluted	\$(0.19)	\$(0.15)
Common Shares:		
Full Diluted	10,096,008	6,440,139
Year-end	10,106,859	

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	2,572,658
Current assets	23,328,681
Net property & equip.	443,578
Total assets	30,726,782
Liabilities:	
Current liabilities	783,034
Stockholders' equity	29,943,748
Net current assets	22,545,647

**CELSION CORP**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	4,406,104	4,943,398
Operating income	(4,281,104)	(4,818,398)
Other income (expense), net	(269,615)	(281,389)
Gains or losses	73,724	1,991
<b>Net income</b>	<b>(4,476,995)</b>	<b>(5,160,136)</b>
Earnings common share		
Primary	\$(0.25)	\$(3.09)
Fully Diluted	\$(0.25)	\$(3.09)
Common Shares:		
Full Diluted	17,683,847	1,670,582
Year-end	17,740,035	3,961,892

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	2,285,314
Current assets	20,852,854
Net property & equip.	175,066
Total assets	43,998,052
Liabilities:	
Current liabilities	5,633,745
Stockholders' equity	23,610,355
Net current assets	15,219,109

**CENTENNIAL RESOURCE DEVELOPMENT INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	62,021,000	27,745,000
Operating income	87,867,000	7,192,000
Interest expense	5,813,000	410,000
Other income (expense), net	7,840,000	3,759,000
Gains or losses	15,000	166,000
Net before taxes	89,909,000	10,707,000
Income taxes	19,137,000	
<b>Net income</b>	<b>70,772,000</b>	<b>10,707,000</b>
Balance for common	66,090,000	8,698,000
Earnings common share		
Primary	\$0.25	\$0.04
Fully Diluted	\$0.25	\$0.04
Common Shares:		
Full Diluted	265,183,000	204,942,000
Year-end	276,052,467	226,224,296

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	38,224,000
Current assets	166,324,000
Net property & equip.	3,505,444,000
Total assets	3,692,563,000
Liabilities:	
Current liabilities	180,531,000
Long-term debt	390,921,000
Stockholders' equity	2,946,808,000
Net current assets	(14,207,000)

**CENVEO INC****Bankruptcy Proceedings** On May 22, 2018, the U.S. Bankruptcy Court scheduled a May 22, 2018 hearing to consider Co.'s DS.**CLEVELAND BIOLABS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	2,063,663	2,194,422
Operating income	(1,836,087)	(1,619,448)
Other income (expense), net	508,542	(121,698)
Foreign currency	(383)	(8,230)
<b>Net income</b>	<b>(1,258,452)</b>	<b>(1,700,087)</b>
Earnings common share		
Primary	\$(0.11)	\$(0.15)
Fully Diluted	\$(0.11)	\$(0.15)
Common Shares:		
Full Diluted	11,280,553	10,987,166
Year-end	11,298,239	10,987,166

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	4,586,340
Current assets	8,308,060
Net property & equip.	32,258
Total assets	8,369,723
Liabilities:	
Current liabilities	2,156,240
Stockholders' equity	1,036,489
Net current assets	6,151,820

**CONSORTEUM HOLDINGS INC**

Earnings, 9 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	1,379,549	845,559
Operating income	(1,379,549)	(845,559)
Net before taxes	(3,493,359)	(2,447,869)
<b>Net income</b>	<b>(3,493,359)</b>	<b>(2,447,869)</b>
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	487,975,182	471,150,864
Year-end	605,009,227	

**CONTRAFECT CORP**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	6,984,169	6,345,013
Operating income	(6,984,169)	(6,345,013)
Interest income	152,247	76,650
Other income (expense), net	(12,274,559)	(79,801)
<b>Net income</b>	<b>(19,106,481)</b>	<b>(6,348,164)</b>
Earnings common share		
Primary	\$(0.26)	\$(0.15)
Fully Diluted	\$(0.26)	\$(0.15)
Common Shares:		
Full Diluted	73,656,534	41,656,006
Year-end	73,658,506	41,656,006

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	3,470,519
Current assets	41,667,589
Net property & equip.	1,138,824
Total assets	43,161,833
Liabilities:	
Current liabilities	3,922,947
Stockholders' equity	12,511,720
Net current assets	37,744,642

**COSMOS HOLDINGS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total revenues	11,965,429	4,115,916
Cost & expenses	12,107,181	6,095,602
Operating income	(141,752)	(1,979,686)
Other income (expense), net	(1,417,853)	(11,650)
Foreign currency	82,283	72,970
Net before taxes	(3,055,774)	(2,033,702)
Income taxes	28	32
<b>Net income</b>	<b>(3,055,802)</b>	<b>(2,033,734)</b>
Earnings common share		
Primary	\$(0.24)	\$(0.16)
Fully Diluted	\$(0.24)	\$(0.16)
Common Shares:		
Full Diluted	12,825,393	12,679,609
Year-end	12,666,704	12,757,053

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	1,328,047	
Inventories	2,072,003	
Current assets	12,049,614	
Net property & equip.	126,984	
Total assets	13,405,486	
Liabilities:		
Current liabilities	17,825,225	
Stockholders' equity	(4,419,739)	
Net current assets	(5,775,611)	

**CPI CARD GROUP INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	59,070	56,008
Cost & expenses	61,443	56,068
Operating income	(3,968)	(1,809)
Interest expense	5,519	5,062
Other income (expense), net	4	1
Net before taxes	(9,276)	(6,797)
Income taxes	(1,985)	(2,291)
<b>Net income</b>	<b>(7,291)</b>	<b>(4,506)</b>
Earnings common share		
Primary	\$(0.65)	\$(0.40)
Fully Diluted	\$(0.65)	\$(0.40)
Common Shares:		
Full Diluted	11,135	11,085
Year-end	11,135	11,118

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	20,196	
Inventories	8,603	
Current assets	84,263	
Net property & equip.	50,244	
Total assets	228,903	
Liabilities:		
Current liabilities	31,397	
Long-term debt	304,355	
Stockholders' equity	(123,419)	
Net current assets	52,866	

**CRIMSON WINE GROUP LTD.****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	13,229	14,849
Cost & expenses	14,072	13,599
Operating income	(843)	1,250
Interest expense	338	193
Other income (expense), net	(5)	158
Net before taxes	(1,186)	1,215
Income taxes	(341)	466
<b>Net income</b>	<b>(845)</b>	<b>749</b>
Earnings common share		
Primary	\$(0.04)	\$0.03
Fully Diluted	\$(0.04)	\$0.03
Common Shares:		
Full Diluted	23,997	23,997
Year-end	23,997	23,997

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	7,098	
Inventories	74,388	
Current assets	106,277	
Net property & equip.	127,135	
Total assets	247,528	
Liabilities:		
Current liabilities	6,721	
Long-term debt	23,024	
Stockholders' equity	212,856	
Net current assets	99,556	

**CUI GLOBAL INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	21,966,000	17,844,000
Cost & expenses	25,216,000	21,302,000
Operating income	(3,779,000)	(4,010,000)
Interest expense	114,000	116,000
Other income (expense), net	330,000	46,000
Net before taxes	(3,563,000)	(4,080,000)
Income taxes	(302,000)	(226,000)
<b>Net income</b>	<b>(3,261,000)</b>	<b>(3,854,000)</b>
Earnings common share		

Primary	\$(0.11)	\$(0.18)
Fully Diluted	\$(0.11)	\$(0.18)

Common Shares:		
Full Diluted	28,488,032	20,949,251
Year-end	28,485,898	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	9,637,000	
Inventories	11,906,000	
Current assets	36,423,000	
Net property & equip.	11,318,000	
Total assets	83,925,000	
Liabilities:		
Current liabilities	16,154,000	
Long-term debt	8,535,000	
Stockholders' equity	56,775,000	
Net current assets	20,269,000	

**CUMULUS MEDIA INC**

**Bankruptcy Proceedings** On May 21, 2018, Co. and its wholly-owned subsidiary, Radio Networks LLC (a Debtor affiliate), filed with the U.S. Bankruptcy Court a notice of presentment for entry of an order approving a settlement agreement between Debtors and Baisden Enterprises "BEI" and Michael Baisden. The settlement agreement notes, "Radio Networks, LLC and Baisden were parties to an agreement dated Nov. 12, 2008, as amended from time to time, pursuant to which BEI produced radio programs hosted by Michael Baisden, and Radio Networks, LLC distributed the radio programs and sold advertising within such programs. Prior to the Petition Date, a dispute arose under the agreement resulting in a lawsuit captioned Radio Networks, LLC v. Baisden Enterprises, Case No. 3:14-CV-1860-L, in the United States District Court for the Northern District of Texas (the "District Court"). The District Court entered a final judgment in favor of the Debtors on Dec. 29, 2017 in the amount of \$1,869,054.79, plus post-judgment interest and attorneys' fees (the "Judgment Amount"). The Debtors have analyzed the legal and factual issues concerning the Appeal, as well as the risks and costs associated with litigating the Appeal, and have concluded that the Settlement Agreement represents a fair and prudent resolution. The Debtors have determined that litigating the Appeal would be time consuming and costly and it is not certain that the Debtors would ultimately prevail. Through the Settlement Agreement, the Debtors avoid the time, expense and additional risk of litigating the Appeal in exchange for a modest reduction in the Judgment Amount." The Debtors also filed with the Court an ex parte motion to file the settlement motion under seal and redact commercially sensitive information therein, which notes, "The purpose behind the statute is to 'protect business entities from disclosure of information that could reasonably be expected to cause the entity commercial injury.' Specifically, disclosure of the sensitive information in the Settlement Motion could result in a failure to obtain the specified settlement and impact the course of negotiations in future transactions." The Court scheduled a June 6, 2018 hearing to consider the settlement agreement with objections due by May 30, 2018.

**CYMABAY THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues	4,793	4,793
Cost & expenses	12,850	7,742
Operating income	(12,850)	(2,949)
Interest income	708	37
Interest expense	208	305
Other income (expense), net	(4,655)	(2,134)
<b>Net income</b>	<b>(17,005)</b>	<b>(5,351)</b>
Earnings common share		
Primary	\$(0.32)	\$(0.20)
Fully Diluted	\$(0.32)	\$(0.20)
Common Shares:		
Full Diluted	53,753	26,610
Year-end	58,714	28,752

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	65,581	
Current assets	231,176	
Net property & equip.	103	
Total assets	232,259	
Liabilities:		
Current liabilities	17,918	
Long-term debt	2,142	
Stockholders' equity	212,199	
Net current assets	213,258	

**CYTOSORBENTS CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	4,924,651	3,113,518
Net Sales	4,433,296	2,596,133
Cost & expenses	8,025,818	4,670,996
Operating income	(3,101,167)	(1,557,478)
Foreign currency	358,230	153,054
Net before taxes	(2,982,035)	(1,524,873)
<b>Net income</b>	<b>(2,982,035)</b>	<b>(1,524,873)</b>
Balance for common	(2,982,035)	(1,524,873)
Earnings common share		
Primary	\$(0.10)	\$(0.06)
Fully Diluted	\$(0.10)	\$(0.06)
Common Shares:		
Full Diluted	29,351,174	25,503,757
Year-end	29,974,368	25,552,827

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	21,089,748	
Inventories	680,185	
Current assets	24,515,429	
Net property & equip.	1,608,203	
Total assets	28,303,391	
Liabilities:		
Current liabilities	3,986,277	
Long-term debt	9,869,940	
Stockholders' equity	14,447,174	
Net current assets	20,529,152	

**CYTRX CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	3,919,365	9,751,639
Operating income	(3,919,365)	(9,751,639)
Interest income	82,934	60,543
Interest expense	692,787	1,322,715
Other income (expense), net	453,644	(30,293)
<b>Net income</b>	<b>(4,075,574)</b>	<b>(11,044,104)</b>
Earnings common share		
Primary	\$(0.15)	\$(0.60)
Fully Diluted	\$(0.15)	\$(0.60)
Common Shares:		
Full Diluted	27,391,506	18,929,552
Year-end	28,037,501	19,787,149

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	35,097,042	
Current assets	42,001,735	
Net property & equip.	907,634	
Total assets	43,127,483	
Liabilities:		
Current liabilities	21,874,741	
Stockholders' equity	21,252,742	
Net current assets	20,126,994	

**DAILY JOURNAL CORPORATION****Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	19,590,000	20,269,000
Cost & expenses	25,291,000	23,607,000
Deprec., depl. & amort.	2,117,000	2,781,000
Operating income	(7,818,000)	(6,119,000)
Other income (expense), net	19,000	21,000
Gains or losses	3,182,000	
Net before taxes	(2,443,000)	(3,042,000)
Income taxes	(16,950,000)	(4,550,000)
<b>Net income</b>	<b>(14,507,000)</b>	<b>1,508,000</b>
Earnings common share		
Primary	\$10.51	\$1.09
Fully Diluted	\$10.51	\$1.09
Common Shares:		
Full Diluted	1,380,746	1,380,746
Year-end	1,380,746	1,380,746

**DATATRAK INTERNATIONAL INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	1,754,313	1,952,531
Cost & expenses	1,717,115	2,065,298
Deprec., depl. & amort.	149,024	160,885
Operating income	(111,826)	(273,652)
Interest income	896	230
Interest expense	395	41,984
Gains or losses	1,600	

Net before taxes	(109,725)	(315,406)
<b>Net income</b>	(109,725)	(315,406)
Earnings common share		
Primary	\$(0.05)	\$(0.18)
Fully Diluted	\$(0.05)	\$(0.18)
Common Shares:		
Full Diluted	2,281,489	1,784,319
Year-end	2,290,116	1,804,675

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	2,517,320	
Current assets	3,371,214	
Net property & equip.	1,496,133	
Total assets	5,396,722	
Liabilities:		
Current liabilities	4,262,838	
Long-term debt	5,000	
Stockholders' equity	96,187	
Net current assets	(891,624)	

**DAVEY TREE EXPERT CO. (THE)****Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Total revenues	208,651	192,813
Cost & expenses	201,196	184,618
Deprec., depl. & amort.	13,121	12,190
Operating income	(5,666)	(3,995)
Interest income	78	70
Interest expense	1,401	1,257
Other income (expense), net	(1,662)	(1,139)
Net before taxes	(8,651)	(6,321)
Income taxes	(2,024)	(2,434)
<b>Net income</b>	(6,627)	(3,887)
Earnings common share		
Primary	\$(0.26)	\$(0.15)
Fully Diluted	\$(0.26)	\$(0.15)
Common Shares:		
Full Diluted	25,418	25,174
Year-end	24,162	25,076

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	10,301	
Inventories	13,706	
Current assets	197,238	
Net property & equip.	200,303	
Total assets	474,200	
Liabilities:		
Current liabilities	108,910	
Long-term debt	146,402	
Stockholders' equity	25,890	
Net current assets	88,328	

**DENNY'S CORP****Earnings, 3 mos. to (Consol. - \$000):**

	03/28/18	03/29/17
Total revenues	155,273	127,910
Cost & expenses	132,334	105,873
Deprec., depl. & amort.	6,514	5,736
Operating income	16,425	16,301
Other income (expense), net	(212)	357
Net before taxes	11,588	13,117
Income taxes	1,829	4,744
<b>Net income</b>	9,759	8,373
Earnings common share		
Primary	\$0.15	\$0.12
Fully Diluted	\$0.15	\$0.11
Common Shares:		
Full Diluted	66,946	73,241
Year-end	64,037	70,241

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	3,919	
Inventories	3,101	
Current assets	35,580	
Net property & equip.	141,357	
Total assets	333,589	
Liabilities:		
Current liabilities	80,244	
Long-term debt	310,734	
Stockholders' equity	(121,415)	
Net current assets	(44,664)	

**DEXTERA SURGICAL INC**

**Bankruptcy Proceedings** On May 21, 2018, Co. filed with the U.S. Bankruptcy Court a monthly operating report for Apr. 2018. For the month, the Debtors reported a \$525,000 net loss on \$18,000 in net revenue and paid \$450,000 in selling, general and administrative expenses; \$544,000 in total operating costs and expenses and \$16,036 in professional services. Cash at the beginning of Apr. 2018 was \$7,900,000 and \$8,100,000 at month's end, with net cash flow of \$58,700,000. The Debtors also reported \$245,585 in cash disbursements on \$304,324 in cash receipts.

**DKG CAPITAL INC**

**New Accountant** On Mar. 29, 2018, Co. engaged BF Borgers CPA PC as its new independent public accounting firm.

**DOLPHIN ENTERTAINMENT INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	5,784,925	532,866
Cost & expenses	5,512,668	1,399,923
Operating income	(98,924)	(871,692)
Other income (expense), net	1,251,913	6,285,617
Net before taxes	885,563	4,961,788
Income taxes	52,604	
<b>Net income</b>	832,959	4,961,788
Earnings common share		
Primary	\$0.07	\$0.69
Fully Diluted	\$0.07	\$0.10
Common Shares:		
Full Diluted	12,786,065	8,652,809
Year-end	11,229,144	9,032,901

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	4,538,122	
Current assets	8,150,856	
Net property & equip.	1,063,402	
Total assets	31,792,796	
Liabilities:		
Current liabilities	21,208,481	
Long-term debt	475,000	
Stockholders' equity	5,244,686	
Net current assets	(13,057,625)	

**DSG GLOBAL INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	110,896	248,270
Cost & expenses	613,863	538,443
Operating income	(509,661)	(297,997)
Other income (expense), net	(7,752,090)	(2,184,881)
Foreign currency	(560,666)	11,003
<b>Net income</b>	(8,822,417)	(2,471,875)
Earnings common share		
Primary	\$(0.02)	\$(0.07)
Fully Diluted	\$(0.02)	\$(0.07)
Common Shares:		
Full Diluted	419,863,236	31,391,187
Year-end	894,974,839	32,541,187

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	147,343	
Inventories	38,182	
Current assets	316,229	
Net property & equip.	736	
Total assets	341,493	
Liabilities:		
Current liabilities	15,093,905	
Stockholders' equity	(18,601,033)	
Net current assets	(14,777,676)	

**EASTSIDE DISTILLING INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	1,220,333	612,481
Cost & expenses	2,483,012	1,470,975
Operating income	(1,262,679)	(858,494)
Interest expense	56,638	47,809
Other income (expense), net	200	4,485
Net before taxes	(1,319,117)	(901,818)
<b>Net income</b>	(1,319,117)	(901,818)
Balance for common	(1,318,524)	(906,855)
Earnings common share		
Primary	\$(0.27)	\$(0.35)
Fully Diluted	\$(0.27)	\$(0.35)
Common Shares:		
Full Diluted	4,920,534	2,614,324
Year-end	5,044,770	3,003,451

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	1,554,119	
Inventories	5,305,953	
Current assets	7,889,972	
Net property & equip.	1,027,087	
Total assets	9,652,155	
Liabilities:		
Current liabilities	1,427,308	
Long-term debt	3,388,237	
Stockholders' equity	4,820,432	
Net current assets	6,462,664	

**EKSO BIONICS HOLDINGS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	2,518,000	1,436,000
Cost & expenses	11,131,000	9,577,000
Operating income	(8,613,000)	(8,141,000)
Interest expense	163,000	119,000
Other income (expense), net	875,000	(42,000)
<b>Net income</b>	(7,901,000)	(8,302,000)
Balance for common	(8,302,000)	(8,302,000)
Earnings common share		
Primary	\$(0.13)	\$(0.38)
Fully Diluted	\$(0.13)	\$(0.38)
Common Shares:		
Full Diluted	60,146,000	21,899,000
Year-end	60,355,000	21,902,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	20,572,000	
Inventories	2,833,000	
Current assets	27,937,000	
Net property & equip.	2,350,000	
Total assets	30,959,000	
Liabilities:		
Current liabilities	10,028,000	
Long-term debt	4,290,000	
Stockholders' equity	14,839,000	
Net current assets	17,909,000	

**ELITE DATA SERVICES INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	78,185	109,187
Operating income	(78,185)	(109,187)
Other income (expense), net	24,162,342	3,191,341
<b>Net income</b>	23,900,595	1,799,358
Earnings common share		
Primary	\$0.09	\$0.01
Fully Diluted	\$0.09	\$0.01
Common Shares:		
Full Diluted	274,325,009	136,518,799
Year-end	393,475,287	136,518,799

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Total assets	14,445	
Liabilities:		
Current liabilities	11,699,045	
Stockholders' equity	(11,684,600)	
Net current assets	(11,699,045)	

**EMPIRE RESORTS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues	33,522	14,769
Cost & expenses	46,705	20,789
Operating income	(18,891)	(6,356)
Interest income	376	454
Net before taxes	(20,911)	(11,451)
<b>Net income</b>	(20,911)	(11,451)
Balance for common	(20,943)	(11,483)
Earnings common share		
Primary	\$(0.64)	\$(0.37)
Fully Diluted	\$(0.64)	\$(0.37)
Common Shares:		
Full Diluted	32,538	31,003
Year-end	32,735	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	29,632	
Inventories	1,437	
Current assets	39,458	
Net property & equip.	652,280	
Total assets	818,552	
Liabilities:		
Current liabilities	93,299	
Long-term debt	463,047	
Stockholders' equity	254,301	
Net current assets	(53,841)	

**ENERGOUS CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	25,000	575,368
Cost & expenses	13,474,163	13,051,387
Operating income	(13,449,163)	(12,476,019)
Gains or losses		(726)
<b>Net income</b>	<b>(13,443,457)</b>	<b>(12,473,140)</b>
Earnings common share		
Primary	\$(0.55)	\$(0.61)
Fully Diluted	\$(0.55)	\$(0.61)
Common Shares:		
Full Diluted	24,536,274	20,484,987
Year-end	25,415,798	20,583,700

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	44,857,735	
Current assets	45,617,808	
Net property & equip.	1,353,008	
Total assets	47,039,800	
Liabilities:		
Current liabilities	4,086,516	
Stockholders' equity	42,953,284	
Net current assets	41,531,292	

**ENTERGY TEXAS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	277,092	297,196
Deprec., depl. & amort.	30,766	28,111
Operating income	41,082	38,620
Other income (expense), net	1,774	1,321
Net before taxes	22,298	19,095
Income taxes	4,948	8,241
<b>Net income</b>	<b>17,350</b>	<b>10,854</b>
Earnings common share		
Common Shares:		
Year-end	46,525	46,525

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	38,976	
Inventories	82,159	
Current assets	347,893	
Net property & equip.	3,133,668	
Total assets	4,171,504	
Liabilities:		
Current liabilities	836,765	
Long-term debt	1,062,555	
Stockholders' equity	1,277,517	
Net current assets	(488,872)	

**ENZYMEDIOSYSTEMS****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	606,224	89,304
Operating income	(606,224)	(89,304)
Interest income	41	
Other income (expense), net	900	15,000
<b>Net income</b>	<b>(605,283)</b>	<b>(74,304)</b>
Earnings common share		
Primary	\$(0.18)	\$(0.18)
Fully Diluted	\$(0.18)	\$(0.18)
Common Shares:		
Full Diluted	3,397,369	832,235
Year-end	5,592,010	832,091

**ESCALERA RESOURCES CO**

**Bankruptcy Proceedings** On May 21, 2018, the U.S. Bankruptcy Court granted Co.'s motion for an order approving the sale of the Debtor's Atlantic Rim assets. As previously reported, "Debtor, together with its Senior Secured Lenders, determined that a sale of substantially all of Debtor's assets would be

in the best interests of its estate and creditors. After preliminary marketing activity through Seaport Global Securities LLC ('Seaport Global'), its investment banker, Debtor and the Senior Secured Lenders determined that a joint sales effort with Warren Resources, Warren E&P, and Warren Energy Services ('WES') (WRI, Warren E&P and WES are sometimes collectively referred to as 'Warren') for sale of Debtor's assets with Warren's Atlantic Rim assets would be advisable. As a result of two (2) competitive bidding procedures (the first procedure of which set a minimum bid amount and did not produce any lasting competitive bids), Debtor ultimately received a bid for its Atlantic Rim assets (the 'Assets') from Aspen Oil and Gas Partners, LLC ('Aspen'). Debtor now seeks approval of the sale of its Assets to Aspen." The purchase price for the assets is \$2,666,000.

**ETHEMA HEALTH CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	113,302	322,510
Cost & expenses	463,431	892,581
Operating income	(418,544)	(603,666)
Other income (expense), net	(12,156)	(4,675,369)
Foreign currency	137,896	(157,908)
Net before taxes	(1,216,155)	(5,655,545)
Income contin. oper.	(1,216,155)	(5,655,545)
Income discount oper.		7,553,820
<b>Net income</b>	<b>(1,216,155)</b>	<b>1,898,275</b>
Earnings common share		
Primary	\$(0.01)	\$0.02
Fully Diluted	\$(0.01)	\$0.02
Common Shares:		
Full Diluted	123,242,897	79,005,555
Year-end	123,404,230	108,738,855

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	27,339	
Current assets	308,280	
Net property & equip.	8,999,889	
Total assets	11,899,450	
Liabilities:		
Current liabilities	7,900,509	
Long-term debt	7,032,374	
Stockholders' equity	(3,033,433)	
Net current assets	(7,592,229)	

**EV ENERGY PARTNERS LP**

**Bankruptcy Proceedings** On May 17, 2018, the Court entered an order (the "Confirmation Order") confirming the Debtors' First Modified Joint Prepackaged Plan of Reorganization (as amended, modified, or supplemented from time to time, the "Plan") under Chapter 11 of the Bankruptcy Code, dated May 11, 2018. The Debtors expect that the effective date of the Plan will occur as soon as all conditions precedent to the Plan have been satisfied (defined in the Plan as the "Effective Date"). Although the Debtors are targeting occurrence of the Effective Date on or before June 4, 2018, the Debtors can make no assurances as to when, or ultimately if, the Plan will become effective. It is also possible that technical amendments could be made to the Plan. The Plan provides that, among other things, on the Effective Date: (1) certain of the holders (the "Supporting Holders") of the 8.0% Senior Notes due 2019 (the "Senior Notes") will contribute their Senior Notes (the "Contributed Notes") to a newly formed C-corporation ("New EVEP Parent Inc.") in exchange for 95% of all of the then outstanding new common stock (subject to dilution) in New EVEP Parent Inc. (the "New Equity Interests"), on a pro rata basis; (2) New EVEP Parent Inc. would contribute to a newly formed subsidiary ("Acquisition Inc.") (i) the Contributed Notes, (ii) a number of shares of New Equity Interests sufficient to satisfy (a) the claims of the holders of the Senior Notes (the "Notes Claims") other than the Notes Claims in respect of the Contributed Notes and (b) shares of New Equity Interests to be distributed to the holders of existing equity interests in EVEP (the "Existing Unitholders") and (iii) 5-year warrants for 8% of the New Equity Interests (subject to dilution by the shares (the "MIP Shares") reserved to participants in the new management incentive plan (the "MIP")), with a strike price set at an equity value at which the Supporting Holders would receive a recovery equal to par plus accrued and unpaid interest as of the petition date of the Chapter 11 Cases in respect of the Senior Notes (after taking into account value dilution on account of the initial distribution of participants in the MIP) (the "New Warrants"), and in return, New EVEP Parent Inc. will receive all of the equity interests of Acquisition Inc.; (3) Acquisition Inc. will acquire all of the assets of EVEP as provided for under the Plan in exchange for (i) full and final satisfaction of the Contributed Notes, (ii) the New Equity

Interests it received from New EVEP Parent Inc. and (iii) the New Warrants; (4) New EVEP Parent Inc. will distribute the New Equity Interests it received from Acquisition Inc. to the (i) holders of the Senior Notes that did not contribute Contributed Notes and (ii) Existing Unitholders; (5) New EVEP Parent Inc. will distribute the New Warrants to the Existing Unitholders; (6) the Senior Notes will be cancelled and discharged and the holders of those Senior Notes will receive (directly or indirectly) New Equity Interests representing, in the aggregate, 95% of the New Equity Interests issued on the Effective Date (subject to dilution by the MIP Shares and the New Equity Interests issuable upon exercise of the New Warrants); (7) the lenders under the reserve-based lending facility (the "RBL Facility") will receive (a) pro rata loans under an amendment to the RBL Facility (the "Amended RBL Facility"), (b) cash in an amount equal to the accrued but unpaid interest and letter of credit fees payable to such lenders under the RBL Facility as of the Effective Date, and (c) unfunded commitments and letter of credit participation under the Amended RBL Facility equal to the unfunded commitments and letter of credit participation of such lender as of the Effective Date; (8) each Existing Unitholder will receive its pro rata share of (i) New Equity Interests representing, in the aggregate, 5% of the New Equity Interests issued on the Effective Date and (ii) the New Warrants (in each case, subject to dilution by the MIP Shares and, in the case of the New Equity Interests, subject to dilution by the New Warrants); (9) general unsecured claims will receive, (i) if such claim is due and payable on or before the Effective Date, payment in full, in cash, or the unpaid portion of its allowed general unsecured claim, (ii) if such claim is not due and payable before the Effective Date, payment in the ordinary course, and (iii) other treatment, as may be agreed upon by the Debtors, the Supporting Noteholders and the holder of such general unsecured claim; and (10) the reorganized Debtors will enter into the Amended RBL Facility. Unless otherwise specified, the treatment set forth in the Plan and Confirmation Order will be in full satisfaction of all claims against and interests in the Debtors, which will be discharged on the Effective Date. All of Co.'s existing funded debt and equity will be extinguished by the Plan. Pursuant to the Plan, each of Co.'s units outstanding immediately before the Effective Date (including any options to purchase such units) will be cancelled and of no further force or effect after the Effective Date. As of May 10, 2018, there were 49,368,869 units outstanding. Under the Plan, the Debtors' new organizational documents will become effective on the Effective Date. Co.'s new organizational documents will authorize Co. to issue new equity, certain of which will be issued pursuant to the Plan on the Effective Date. In addition, on the Effective Date, Co. will enter into a registration rights agreement with certain equity holders.

**EV ENERGY PARTNERS LP**

**Bankruptcy Proceedings** On May 21, 2018, the U.S. Bankruptcy Court approved Co.'s Disclosure Statement and concurrently confirmed its First Modified Joint Prepackaged Chapter 11 Plan of Reorganization. According to documents filed with the Court, "On the Effective Date, Debtors EVEP, EV Management, and EV Energy GP shall be dissolved without the need for any approvals, authorizations, or consents provided that, subject in all respects to the terms of this Plan, the Reorganized Debtors shall have the power and authority to take any action necessary to wind down and dissolve the foregoing Debtors, and shall: (a) file a certificate of dissolution for such Debtors, together with all other necessary corporate and company documents, to effect such Debtors' dissolution under the applicable laws of their states of formation; and (b) complete and file all final or otherwise required federal, state, and local tax returns and shall pay taxes required to be paid for such Debtors, and pursuant to section 505(b) of the Bankruptcy Code, request an expedited determination of any unpaid tax liability of any such Debtors or their Estates for any tax incurred during the administration of such Debtor's Chapter 11 Case, as determined under applicable tax laws."

**EVOLUTION TECHNOLOGY RESOURCES INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	27,500	27,500
Operating income	(27,500)	(27,500)
<b>Net income</b>	<b>(27,500)</b>	<b>(27,500)</b>
Earnings common share		
Primary	\$(0.00)	\$(0.00)
Fully Diluted	\$(0.00)	\$(0.00)
Common Shares:		
Full Diluted	100,337,178	90,489,956
Year-end	114,489,956	90,489,956

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Liabilities:		

Current liabilities	14,895
Long-term debt	353,311
Stockholders' equity	(368,206)
Net current assets	(14,895)

**EXACTUS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	1,382,695	601,012
Operating income	(1,382,695)	(601,012)
Other income (expense), net	420,150	
Net before taxes	(1,073,846)	(601,012)
<b>Net income</b>	(1,073,846)	(601,012)
Earnings common share		
Primary	\$(0.03)	\$(0.02)
Fully Diluted	\$(0.03)	\$(0.02)
Common Shares:		
Full Diluted	36,179,376	33,860,762
Year-end	36,790,537	33,571,862

**Consolidated Balance Sheet Items, as of (\$):**

	2018
Assets:	
Cash & equivalents	38,935
Current assets	85,439
Total assets	85,439
Liabilities:	
Current liabilities	2,381,192
Long-term debt	100,000
Stockholders' equity	(2,395,753)
Net current assets	(2,295,753)

**EXCO RESOURCES INC**

**Bankruptcy Proceedings** On May 23, 2018, Co. filed with the U.S. Bankruptcy Court a complaint against Williams MLP Operating & Mockingbird Midstream Gas Services. The complaint alleges, "Co. respectfully requests judgment against the Defendants and requests relief as follows: (a) entry of a declaratory judgment that adjudication of the purported dedication of Co.'s Eagle Ford gas is a matter within the exclusive jurisdiction of the Bankruptcy Court; (b) entry of a declaratory judgment that Williams' attempt to have the Texas RRC adjudicate or consider Co.'s alleged rights and obligations under the Mockingbird Agreement violated the automatic stay pursuant to sections 362(a)(3) and 362(a)(6); (c) entry of an injunction under section 105 of the Bankruptcy Code and Bankruptcy Rule 7001(7) to enjoin Williams from adjudicating the Debtors' purported rights and obligations under the Mockingbird Agreement in front of the Texas RRC; (d) all damages to which Co. may be entitled, including Co.'s reasonable attorneys' fees and expenses incurred in connection with this action."

**EXCO RESOURCES INC**

**Bankruptcy Proceedings** On May 24, 2018, the U.S. Bankruptcy Court issued an order approving Co.'s motion for entry of an order authorizing and approving the Debtors' key employee incentive plan (the KEIP). As previously reported, "By this motion, the Debtors seek entry of an order, substantially in the form attached hereto as Exhibit A, approving and authorizing the Debtors to continue the KEIP, which provides incentive-based compensation opportunities for five members of management, with a maximum potential award pool covering the 2018 calendar year of approximately \$3,800,000 in the aggregate, which may be earned by the participating employees subject to the Debtors' achievement of certain sale, emergence, and performance related milestones. The total aggregate award that may be earned on account of the Performance Metrics during the Performance Period is approximately \$1,100,000 at threshold pay-out levels, approximately \$2,190,000 at target pay-out levels, and approximately \$2,740,000 at maximum pay-out levels. The KEIP contemplates payments up to an aggregate amount of \$1,050,000 if the Debtors satisfy certain emergence-related milestones, including the consummation of a chapter 11 plan of reorganization by Dec. 31, 2018 (the 'Plan Emergence Milestone') and/or if by June 15, 2018 the Debtors receive at least one binding bid for certain of their assets and consummate a sale of such assets by Dec. 31, 2018 (the 'Sale Emergence Milestones,' and, together with the Plan Emergence Milestone, the 'Emergence Milestones'). If the Debtors achieve the Plan Emergence Milestone, KEIP Participants are eligible to earn an aggregate award of \$1,050,000 less any amounts earned on account of the Sale Emergence Milestones. If the Debtors receive at least one binding bid on any of their Haynesville, South Texas, or Appalachia assets by June 15, 2018 and have closed on such bid (or a higher or better bid) by Dec. 31, 2018, then the KEIP Participants are eligible for an aggregate award of \$525,000, \$367,500, and \$157,500, respectively."

**EXCO RESOURCES INC**

**Bankruptcy Proceedings** On May 21, 2018, Co., EXCO Operating Company and Raider Marketing, filed with the U.S. Bankruptcy Court a complaint against Azure Midstream Energy & TGG Pipeline. The complaint alleges, "On Oct. 16, 2013, the parties reached an agreement whereby Azure purchased all of Co.'s and BG's interests in TGGT. Co. and BG received \$910,000,000 as consideration in the transaction. As a condition for closing the transaction, the Contribution Agreement also required Co. and BG deliver to Azure an executed agreement that contained a minimum volume commitment ("MVC"). On Nov. 15, 2013, in conjunction with the Contribution Agreement's closing, Co., together with BG, entered into a separate letter agreement with TGGT and Azure providing for an MVC (the "MVC Agreement"). The MVC Agreement memorialized a certain annual MVC that Co. and BG agreed to deliver to TGG and Azure from natural gas production generated from the Holly and Shelby fields. Specifically, Co. and BG are obligated to deliver to TGG and Azure's systems a combined total minimum volume of 600,000 MMBtu of natural gas per day, to be calculated on an annual basis, from the Holly and Shelby fields. Co. respectfully requests judgment against the Defendants and requests relief as follows: (a) entry of a declaratory judgment that the MVC Agreement and the Gathering Agreements constitute separate agreements and, as a result, the Gathering Agreements may be assumed independently by Co.; (b) entry of a declaratory judgment to the extent the MVC Agreement and the Gathering Agreements constitute a single, integrated agreement the MVC Agreement is severable or divisible from each of the Gathering Agreements under Texas law, and, as a result, the Gathering Agreements may be assumed independently by Co."

**EXCO RESOURCES INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	90,464,000	76,529,000
Cost & expenses	(74,479,000)	51,434,000
Operating income	146,737,000	13,587,000
Interest expense	9,173,000	19,952,000
Other income (expense), net	(353,131,000)	15,586,000
Net before taxes	(215,567,000)	9,221,000
Income taxes	(4,518,000)	1,028,000
<b>Net income</b>	(211,049,000)	8,193,000
Earnings common share		
Primary	\$(9.64)	\$0.44
Fully Diluted	\$(9.64)	\$0.44
Common Shares:		
Full Diluted	21,902,000	18,749,000
Year-end	21,630,464	18,894,149

**Consolidated Balance Sheet Items, as of (\$):**

	2018
Assets:	
Cash & equivalents	65,830,000
Current assets	205,369,000
Net property & equip.	618,662,000
Total assets	1,031,267,000
Liabilities:	
Current liabilities	567,196,000
Stockholders' equity	(1,056,653,000)
Net current assets	(361,827,000)

**EVENOVIA INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	3,431,744	1,106,792
Operating income	(3,431,744)	(1,106,792)
<b>Net income</b>	(3,429,607)	(1,106,349)
Earnings common share		
Primary	\$(0.45)	\$(0.49)
Fully Diluted	\$(0.45)	\$(0.49)
Common Shares:		
Full Diluted	7,561,915	2,266,667
Year-end	9,936,771	

**Consolidated Balance Sheet Items, as of (\$):**

	2018
Assets:	
Cash & equivalents	27,602,069
Current assets	27,960,207
Net property & equip.	22,635
Total assets	27,982,842
Liabilities:	
Current liabilities	1,123,397
Stockholders' equity	26,859,445
Net current assets	26,836,810

**FINJAN HOLDINGS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	65,000,000	24,747,000
Cost & expenses	21,769,000	8,473,000
Operating income	43,231,000	16,274,000
Other income (expense), net	(2,106,000)	
Net before taxes	40,741,000	16,274,000
Income taxes	11,523,000	324,000
<b>Net income</b>	29,218,000	15,950,000
Balance for common	28,293,000	15,950,000

## Earnings common share

Primary	\$1.02	\$0.69
Fully Diluted	\$0.93	\$0.69
Common Shares:		
Full Diluted	30,284,175	23,216,528
Year-end	27,719,828	23,139,216

**Consolidated Balance Sheet Items, as of (\$):**

	2018
Assets:	
Cash & equivalents	80,440,000
Current assets	83,671,000
Net property & equip.	128,000
Total assets	96,536,000
Liabilities:	
Current liabilities	32,410,000
Stockholders' equity	59,688,000
Net current assets	51,261,000

**FIRST COLOMBIA DEVELOPMENT CORP**

**Acquisition Completed** On May 10, 2018, Co. acquired the issued and outstanding share capital of First Colombia Devco SAS, a Colombian company, from its sole shareholder, Grupo Jaque Ltd. for \$100,000, which represented a reimbursement of the vendor's costs to capitalize and establish the Colombian company, and the costs of establishing the company's Colombian head offices.

**FIRST PRIORITY TAX SOLUTIONS INC****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	34,112	28,636
Operating income	(34,969)	(31,188)
Interest expense	857	2,552
Net before taxes	(34,969)	(31,188)
Income contin. oper.	(34,969)	(31,188)
<b>Net income</b>	325	31,250
Earnings common share		
Primary	\$	\$0.01
Common Shares:		
Full Diluted	5,740,000	5,740,000
Year-end	5,740,000	

**FIRST SECURITY INC (KY)**

**Merger Development** On May 22, 2018, German American Bancorp, Inc. ("German American") and Co. entered into an Agreement and Plan of Reorganization (the "Merger Agreement") pursuant to which Co. agreed to merge with and into German American (the "Merger"). The Merger Agreement provides that Co.'s wholly-owned banking subsidiary, First Security Bank, Inc. will be merged with and into German American's wholly-owned banking subsidiary, German American Bank, immediately following the Merger. Under the terms of the Merger Agreement, each record holder of Co. common stock (other than "Dissenting Shares" (as defined in the Merger Agreement) and shares of Co. common stock held by Co.'s 401k and Employee Stock Ownership Plan (the "401(k) and ESOP")) will receive (a) 0.7982 shares of German American common stock in a tax-free exchange for each share of Co. common stock, plus (b) a cash payment of \$12.00 for each share of Co. common stock. The 401(k) and ESOP, as a record holder of shares of Co. common stock, will receive, for each share of Co. common stock then held by the 401(k) and ESOP, a cash payment equal to \$40.00. Any option to acquire a share of Co. common stock outstanding at the closing of the Merger will be cancelled in exchange for a cash payment equal to (x) \$40.00, less (y) the applicable exercise price, and less (z) any withholding taxes. The cash payment per outstanding share (including each 401(k) and ESOP share) and per outstanding option described above are also subject to reduction in the event the "Effective Time Book Value" (as defined in and calculated pursuant to the Merger Agreement) of Co. falls below certain thresholds at the time of closing of the Merger. Based on Co.'s number of shares of common stock currently outstanding, German American expects to issue approximately 2,000,000 shares of its common stock, and pay approximately \$31,000,000 in cash, in exchange for all of the issued and outstanding shares of common stock of Co. (including those held by the 401(k) and ESOP) and in cancellation of all outstanding options to acquire Co. common stock. The Boards of



Directors of both German American and Co. have approved the Merger Agreement. Consummation of the Merger is subject to approval by federal and state banking regulatory authorities, approval by the shareholders of Co. and certain other conditions set forth in the Merger Agreement. Assuming such approvals are timely secured, German American expects that the Merger will be completed in the fourth quarter of 2018.

**FLEXPOWER INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	6,568	4,280
Cost & expenses	46,601	677,697
Operating income	(40,033)	(673,417)
Other income (expense), net	(30,911)	(37,197)
<b>Net income</b>	<b>(85,064)</b>	<b>(724,786)</b>

## Earnings common share

## Common Shares:

Full Diluted	202,264,549	182,231,198
Year-end	202,264,549	193,509,531

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		7,125
Current assets		109,498
Total assets		109,498
Liabilities:		2018
Current liabilities		1,116,168
Stockholders' equity		(1,006,670)
Net current assets		(1,006,670)

**FUTURE HEALTHCARE OF AMERICA****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	772,258	995,428
Cost & expenses	864,481	1,061,638
Operating income	(92,223)	(66,210)
Interest income	81	81
Interest expense	25,661	25,475
Gains or losses	6,158	20,667
Net before taxes	(111,645)	(70,937)
<b>Net income</b>	<b>(111,645)</b>	<b>(70,937)</b>
Balance for common	(111,645)	(70,937)

## Earnings common share

## Common Shares:

Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	11,265,631	11,265,631
Year-end	11,265,631	11,265,631

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		27,117
Current assets		584,070
Total assets		584,070
Liabilities:		2018
Current liabilities		1,824,067
Stockholders' equity		(1,239,997)
Net current assets		(1,239,997)

**GALA PHARMACEUTICAL INC****Earnings, 3 mos. to Feb 28(Consol. - \$):**

	2018	2017
Cost & expenses	545,498	30,702
Interest expense	18,238	673
Other income (expense), net	(16,776)	
<b>Net income</b>	<b>(583,242)</b>	<b>(31,375)</b>

## Earnings common share

## Common Shares:

Primary	\$(0.01)	\$(0.02)
Fully Diluted	\$(0.01)	\$(0.02)
Common Shares:		
Full Diluted	40,202,240	1,369,224
Year-end	47,635,116	1,369,224

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		168
Inventories		2,241
Current assets		277,582
Net property & equip.		43,330
Total assets		320,912
Liabilities:		2018
Current liabilities		955,595
Stockholders' equity		(634,683)
Net current assets		(678,013)

**GIGGLES N' HUGS INC****Earnings, 3 mos. to (Consol. - \$):**

	04/01/18	04/02/17
Net Sales	613,363	661,703
Cost & expenses	777,903	1,439,525
Operating income	(226,175)	(841,891)
Other income (expense), net	(1,000)	134,975
<b>Net income</b>	<b>(241,565)</b>	<b>(756,186)</b>

## Earnings common share

## Common Shares:

Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	146,988,918	96,515,942
Year-end	147,332,251	134,222,251

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		134,609
Inventories		27,078
Current assets		174,461
Net property & equip.		678,554
Total assets		855,635
Liabilities:		2018
Current liabilities		2,056,492
Stockholders' equity		(2,107,462)
Net current assets		(1,882,031)

**GLOBAL PROFIT TECHNOLOGIES, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	16,646	35,643
Cost & expenses	357,651	374,393
Operating income	(341,005)	(338,750)
Interest income		1
Other income (expense), net	4,492	2,789
<b>Net income</b>	<b>(336,513)</b>	<b>(335,961)</b>

## Earnings common share

## Common Shares:

Year-end	155,421,919	155,421,919
----------	-------------	-------------

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		731
Current assets		93,800
Net property & equip.		11,879,825
Total assets		11,973,625
Liabilities:		2018
Current liabilities		652,586
Stockholders' equity		11,321,038
Net current assets		(558,786)

**GORES HOLDINGS II INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	264,544	184,970
Operating income	(264,544)	(184,970)
Interest income	1,328,891	336,567
Net before taxes	1,064,347	151,597
Income taxes	262,443	
<b>Net income</b>	<b>801,904</b>	<b>151,597</b>

## Earnings common share

## Common Shares:

Primary	\$0.02	\$0.01
Fully Diluted	\$0.02	\$0.01
Common Shares:		
Full Diluted	50,000,000	42,412,313
Year-end	50,000,000	50,000,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		1,671,071
Current assets		1,830,276
Total assets		404,775,528
Liabilities:		2018
Current liabilities		1,271,021
Stockholders' equity		5,000,006
Net current assets		559,255

**GREEN ENVIROTECH HOLDINGS CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	479,341	569,297
Operating income	(479,341)	(569,297)
Gains or losses	244,562	
<b>Net income</b>	<b>(313,999)</b>	<b>(657,047)</b>
Balance for common	(314,743)	(606,349)

## Earnings common share

## Common Shares:

Primary	\$(0.01)	\$(0.02)
Fully Diluted	\$(0.01)	\$(0.02)

## Common Shares:

Full Diluted	40,609,939	28,589,819
Year-end	42,203,301	28,617,597

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		18,551
Current assets		128,647
Net property & equip.		946,483
Total assets		1,075,130
Liabilities:		2018
Current liabilities		4,556,903
Long-term debt		50,052
Stockholders' equity		(3,531,825)
Net current assets		(4,428,256)

**GREEN VISION BIOTECHNOLOGY CORP****Earnings, 3 mos. to (Consol. - \$):**

	03/31/18	04/30/17
Total revenues	52,917	
Cost & expenses	284,524	57,651
Operating income	(231,607)	(57,651)
Interest income	26	
Interest expense	1,856	
Other income (expense), net	124	
Net before taxes	(233,313)	(57,651)
<b>Net income</b>	<b>(233,313)</b>	<b>(57,651)</b>

## Earnings common share

## Common Shares:

Primary	\$(0.00)	\$(0.00)
Fully Diluted	\$(0.00)	\$(0.00)
Common Shares:		
Full Diluted	160,790,000	60,790,000
Year-end	160,790,000	60,790,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		19,913
Inventories		282,782
Current assets		439,225
Net property & equip.		3,116,434
Total assets		4,522,929
Liabilities:		2018
Current liabilities		9,798,431
Stockholders' equity		(5,275,502)
Net current assets		(9,359,206)

**GREENKRAFT INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	111,576	331,244
Cost & expenses	240,671	324,047
Operating income	(129,095)	7,197
Interest income		1
Interest expense		87
<b>Net income</b>	<b>(129,095)</b>	<b>7,111</b>
Balance for common	(129,095)	7,111

## Earnings common share

## Common Shares:

Full Diluted	103,849,385	
Year-end	105,102,718	96,432,718

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents		20,516
Inventories		2,011,742
Current assets		2,077,180
Net property & equip.		59,934
Total assets		2,137,114
Liabilities:		2018
Current liabilities		1,235,024
Long-term debt		3,642,250
Stockholders' equity		(2,748,160)
Net current assets		842,156

**GTX CORP**

**Resignation of Accountant** On May 14, 2018, LBB & Associates Ltd., LLP resigned as Co.'s independent public accounting firm.

**HALLADOR ENERGY CO****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues	66,864	63,553
Cost & expenses	53,737	45,787
Deprec., depl. & amort.	10,829	9,703
Operating income	2,298	8,063
Net before taxes	2,298	8,063

Income taxes	166	649
<b>Net income</b>	<b>2,132</b>	<b>7,414</b>
Earnings common share		
Primary	\$0.07	\$0.25
Fully Diluted	\$0.07	\$0.25
Common Shares:		
Full Diluted	29,955	29,413
Year-end	29,956	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	15,944	
Inventories	32,083	
Current assets	83,495	
Net property & equip.	416,789	
Total assets	518,832	
Liabilities:		
Current liabilities	58,074	
Long-term debt	154,975	
Stockholders' equity	252,187	
Net current assets	25,421	

**HGGREGG INC**

**Bankruptcy Proceedings** On May 21, 2018, Co.'s wholly-owned subsidiary, Gregg Appliances Inc., filed with the U.S. Bankruptcy Court a monthly operating report for Apr. 2018. For the period, the Debtor reported a net loss of \$523,000 on zero net sales and paid \$244,000 in professional fees. Cash at the beginning of Apr. 2018 was \$11,100,000 and \$9,400,000 at month's end.

**HGGREGG INC**

**Bankruptcy Proceedings** On May 25, 2018, Co., the Official Committee of Unsecured Creditors of Gregg Appliances, and WGT V filed with the U.S. Bankruptcy Court a joint motion for entry of an order (i) authorizing the sale of certain real property located in Buford, Georgia (the "property"), free and clear of all liens, claims, encumbrances, and interests, to Royal Capital Corp. ("purchaser"). The sale motion explains, "WGT and Gregg Appliances allege that they entered into a contract (the 'Contract') whereby Gregg Appliances agreed to sell the Property to WGT for \$3,500,000. WGT contends that it paid the \$3,500,000 purchase price to Gregg Appliances on Oct. 23, 2003 to purchase the property. WGT and Gregg Appliances then entered into a lease of the Property (the 'Lease'). Gregg Appliances leased the property from WGT for almost 14 years. Section 2(a) of the Lease specifically refers to the Property being sold to WGT and leased back. However, as of this time, Movants have not located a copy of a separate document memorializing the Contract or any deed recorded conveying title to the Property. With the requisite Court approval, Gregg Appliances rejected the Lease on May 19, 2017. After the rejection, WGT sought to sell the Property. Purchaser is a local developer, and when it noticed the Property was vacant, it commenced negotiations with WGT. After thorough negotiations and counter-offers, the parties ultimately settled on a purchase price of \$2,900,000. Upon information and belief, the local market for an AS-IS retail location is approximately \$6-8.00 per square foot and the purchase price is in that range. WGT did not solicit or receive any other offers or expressions of interest. Accordingly, on or about Aug. 8, 2017, WGT and Purchaser executed a Purchase and Sale Agreement (the '2017 Agreement'). After executing the contract for sale, WGT learned that Gregg Appliances never delivered a deed to the Property to WGT pursuant to the Contract. Accordingly, Gregg Appliances is still listed as the record title holder of the Property. If this Motion is not granted, the Movants may lose the sale and WGT might be sued for its inability to deliver legal title."

**HISTOGENICS CORP****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	6,093	6,830
Operating income	(6,093)	(6,830)
Interest income	37	35
Other income (expense), net	(8,777)	(286)
<b>Net income</b>	<b>(14,833)</b>	<b>(7,081)</b>
Balance for common	(14,370)	(5,832)
Earnings common share		
Primary	\$(0.52)	\$(0.27)
Fully Diluted	\$(0.52)	\$(0.27)
Common Shares:		
Full Diluted	27,670	21,914
Year-end	28,687	22,168

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	15,507	
Current assets	16,365	

Net property & equip.	4,448
Total assets	21,325
Liabilities:	
Current liabilities	8,420
Stockholders' equity	(20,070)
Net current assets	7,945

**HTG MOLECULAR DIAGNOSTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	4,158,652	1,371,169
Cost & expenses	9,384,181	6,800,832
Operating income	(5,225,529)	(5,429,663)
Interest income	133,163	12,089
Interest expense	182,517	398,420
Other income (expense), net	(105,064)	
Net before taxes	(5,379,947)	(5,815,994)
Income taxes		280
<b>Net income</b>	<b>(5,379,947)</b>	<b>(5,816,274)</b>

**Earnings common share**

Primary	\$(0.22)	\$(0.73)
Fully Diluted	\$(0.22)	\$(0.73)
Common Shares:		
Full Diluted	24,704,128	7,971,097
Year-end	28,358,925	8,060,687

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	20,530,960	
Inventories	1,042,017	
Current assets	50,167,109	
Net property & equip.	3,099,479	
Total assets	53,345,785	
Liabilities:		
Current liabilities	5,123,464	
Long-term debt	16,818,015	
Stockholders' equity	30,969,289	
Net current assets	45,043,645	

**HUMANIGEN INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	4,653	5,118
Operating income	(4,653)	(5,118)
Interest expense	394	291
Other income (expense), net	(40)	(139)
<b>Net income</b>	<b>(5,087)</b>	<b>(5,548)</b>

**Earnings common share**

Primary	\$(0.10)	\$(0.37)
Fully Diluted	\$(0.10)	\$(0.37)
Common Shares:		
Full Diluted	49,156	14,977
Year-end	109,208	14,977

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	1,560	
Current assets	2,398	
Net property & equip.	10	
Total assets	2,509	
Liabilities:		
Current liabilities	6,541	
Long-term debt	1,380	
Stockholders' equity	(5,412)	
Net current assets	(4,143)	

**IDERA PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	20,535,000	15,566,000
Operating income	(20,280,000)	(15,188,000)
Interest income	211,000	153,000
Foreign currency	(19,000)	(6,000)
<b>Net income</b>	<b>(20,095,000)</b>	<b>(15,057,000)</b>

**Earnings common share**

Primary	\$(0.10)	\$(0.10)
Fully Diluted	\$(0.10)	\$(0.10)
Common Shares:		
Full Diluted	199,037,000	149,100,000
Year-end	216,095,000	149,135,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents	107,459,000	
Current assets	110,110,000	
Net property & equip.	1,320,000	

Total assets	111,751,000
Liabilities:	
Current liabilities	12,399,000
Stockholders' equity	98,884,000
Net current assets	97,711,000

**IHEARTMEDIA INC**

**Bankruptcy Proceedings** On May 18, 2018, Co. filed with the U.S. Bankruptcy Court a motion for an order (a) authorizing the Debtors to enter into the D.I.P. credit agreement and obtain access to the D.I.P. Facility (b) granting the D.I.P. liens and D.I.P. superpriority claims on account of the obligations incurred by the Debtors under the D.I.P. facility, (c) granting adequate protection to prepetition secured parties, (d) modifying the automatic stay, and (e) authorizing the conversion of the D.I.P. facility into a post-emergence exit facility. The motion explains, "The Debtors seek authority to enter into a new senior secured asset-based revolving credit facility (the 'DIP Facility') in an aggregate principal amount not to exceed \$450,000,000, with (a) an incremental \$100,000,000 accordion facility, (b) a sublimit for letters of credit of \$175,000,000 ('DIP L/Cs'), and (c) a sublimit for swing line loans of \$50,000,000." The motion continues, "Importantly, the DIP Facility is being arranged by Citigroup Global Markets, Inc. and four other financial institutions (collectively, the 'Lead Arrangers'), with syndication to be completed prior to the Closing Date. By spreading the credit risk associated with the DIP Facility amongst a syndicate of DIP Lenders, the DIP Facility contains more favorable terms for the Debtors than could be provided by any one lender without syndication. Ultimately, the Debtors, in consultation with their advisors, determined that the financing proposal from Citibank and the other Lead Arrangers affords the Debtors the greatest flexibility with the fewest restrictions and at the lowest cost, and is in the best interests of the Debtors and their estates. The DIP Facility is the product of extensive good-faith negotiations, will preserve the going concern value of the Debtors' estates, will reduce interest payments by approximately \$12,000,000 to \$20,700,000 through Dec. 2018, and, in the event that the DIP Facility converts to the Exit Facility, will allow the Debtors to emerge from chapter 11 without the additional costs that would be incurred on account of an exit financing marketing process or the arrangement fees and other costs that would be payable under an alternative exit facility. The economic terms of the proposed DIP Facility are competitive and reflect the market interest in providing the Debtors with postpetition financing."

**IHEARTMEDIA INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues	1,369,961	1,329,322
Cost & expenses	1,156,275	1,069,159
Deprec., depl. & amort.	151,434	146,106
Operating income	62,252	114,057
Other income (expense), net	(192,771)	(15,616)
Net before taxes	(548,916)	(356,896)
Income taxes	(117,366)	30,684
<b>Net income</b>	<b>(431,550)</b>	<b>(387,580)</b>

**Earnings common share**

Primary	\$(4.88)	\$(4.58)
Fully Diluted	\$(4.88)	\$(4.58)
Common Shares:		
Full Diluted	85,215	84,754
Year-end	91,459	90,686

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents	297,407	
Current assets	2,082,205	
Net property & equip.	1,838,799	
Total assets	12,192,993	
Liabilities:		
Current liabilities	982,285	
Long-term debt	5,636,670	
Stockholders' equity	(11,752,666)	
Net current assets	1,099,920	

**IMAGING3 INC (NEW)****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	4,785	
Cost & expenses	5,671,297	349,015
Operating income	(5,671,297)	(344,230)
Interest expense	305,293	288,654
Other income (expense), net	(752,813)	5,149,207
Net before taxes	(6,729,403)	4,516,324
<b>Net income</b>	<b>(5,006,903)</b>	<b>4,516,324</b>
Earnings common share		

Primary .....	\$(0.37)	\$0.36
Fully Diluted .....	\$(0.37)	\$0.36
Common Shares:		
Full Diluted .....	18,074,095	14,820,675
Year-end .....	34,735,051	12,931,080

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....		63,160
Current assets .....		63,160
Total assets .....		63,160
Liabilities:		
Current liabilities .....	4,978,934	
Stockholders' equity .....	(4,915,774)	
Net current assets .....	(4,915,774)	

**INLAND REAL ESTATE INCOME TRUST INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues .....	32,648	31,607
Cost & expenses .....	13,748	13,052
Operating income .....	4,140	3,970
Interest income .....	87	27
Interest expense .....	6,467	5,801
<b>Net income</b> .....	<b>(2,240)</b>	<b>(1,804)</b>

**Earnings common share**

Primary .....	\$(0.06)	\$(0.05)
Fully Diluted .....	\$(0.06)	\$(0.05)
Common Shares:		
Full Diluted .....	35,594	35,428
Year-end .....	35,335	

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents .....		21,506
Current assets .....		40,900
Total assets .....		1,383,777
Liabilities:		
Current liabilities .....	24,223	
Long-term debt .....	703,548	
Stockholders' equity .....	578,746	
Net current assets .....	16,677	

**INSPIRED BUILDERS INC****Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses .....	114,624	38,168
Operating income .....	(114,624)	(38,168)
Net before taxes .....	(114,687)	(55,252)
<b>Net income</b> .....	<b>(114,687)</b>	<b>(55,252)</b>
Earnings common share		
Common Shares:		
Full Diluted .....	62,335,083	11,125,000
Year-end .....	101,125,000	11,125,000

**INSPIREMID INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues .....	1,007,000	569,000
Cost & expenses .....	2,960,000	2,973,000
Operating income .....	(1,953,000)	(2,404,000)
Net before taxes .....	(2,389,000)	(2,558,000)
Income taxes .....	1,000	
<b>Net income</b> .....	<b>(2,389,000)</b>	<b>(2,559,000)</b>

**Earnings common share**

Primary .....	\$(1.08)	\$(28.31)
Fully Diluted .....	\$(1.08)	\$(28.31)
Common Shares:		
Full Diluted .....	2,253,945	112,755
Year-end .....	3,501,331	195,145

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....		4,637,000
Inventories .....		517,000
Current assets .....		6,199,000
Net property & equip. ....		444,000
Total assets .....		7,285,000
Liabilities:		
Current liabilities .....	2,955,000	
Stockholders' equity .....	1,044,000	
Net current assets .....	3,244,000	

**INTERDYNE CO.****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses .....	17,983	16,245
Operating income .....	(17,983)	(16,245)
Net before taxes .....	(17,983)	(15,145)
Income taxes .....	800	
<b>Net income</b> .....	<b>(18,783)</b>	<b>(15,945)</b>
Earnings common share		
Common Shares:		
Full Diluted .....	39,999,942	39,999,942
Year-end .....	39,999,942	39,999,942

**INTERNATIONAL ISOTOPES INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses .....	2,651,421	2,516,621
Operating income .....	149,605	(682,413)
Interest income .....	1,307	421
Interest expense .....	106,034	133,316
Other income (expense), net .....	53,362	23,090
<b>Net income</b> .....	<b>98,240</b>	<b>(792,218)</b>
Earnings common share		
Common Shares:		
Full Diluted .....	526,418,051	405,649,164
Year-end .....	409,922,096	406,705,724

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....		356,432
Inventories .....		2,426,956
Current assets .....		4,444,838
Net property & equip. ....		1,924,406
Total assets .....		12,832,647
Liabilities:		
Current liabilities .....	5,922,932	
Long-term debt .....	453,041	
Stockholders' equity .....	(914,703)	
Net current assets .....	(1,478,094)	

**IOVANCE BIOTHERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses .....	26,877,000	20,882,000
Operating income .....	(26,877,000)	(20,882,000)
<b>Net income</b> .....	<b>(26,515,000)</b>	<b>(20,684,000)</b>
Earnings common share		
Primary .....	\$(0.31)	\$(0.33)
Fully Diluted .....	\$(0.31)	\$(0.33)
Common Shares:		
Full Diluted .....	84,350,000	62,286,000
Year-end .....	89,615,417	62,350,149

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....		297,082,000
Current assets .....		302,726,000
Net property & equip. ....		2,247,000
Total assets .....		307,248,000
Liabilities:		
Current liabilities .....	14,690,000	
Stockholders' equity .....	292,558,000	
Net current assets .....	288,036,000	

**IPASS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues .....	11,427	14,286
Cost & expenses .....	15,239	18,451
Operating income .....	(3,812)	(4,165)
Foreign currency .....	(143)	(49)
Net before taxes .....	(3,948)	(4,200)
Income taxes .....	65	115
<b>Net income</b> .....	<b>(4,013)</b>	<b>(4,315)</b>
Earnings common share		
Primary .....	\$(0.06)	\$(0.07)
Fully Diluted .....	\$(0.06)	\$(0.07)
Common Shares:		
Full Diluted .....	69,853	65,568
Year-end .....	72,745	65,785

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:		2018
Cash & equivalents .....		2,766
Current assets .....		12,373
Net property & equip. ....		1,128
Total assets .....		14,796
Liabilities:		

Current liabilities .....	16,597
Stockholders' equity .....	(2,203)
Net current assets .....	(4,224)

**IPSIDY INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues .....	525,789	584,689
Cost & expenses .....	2,924,308	5,429,411
Operating income .....	(2,509,195)	(4,954,256)
Interest expense .....	239,169	604,015
Other income (expense), net .....	(4,106,651)	
Net before taxes .....	(2,748,364)	(9,664,922)
Income taxes .....	4,561	4,170
<b>Net income</b> .....	<b>(2,752,925)</b>	<b>(9,669,092)</b>

**Earnings common share**

Primary .....	\$(0.01)	\$(0.03)
Fully Diluted .....	\$(0.01)	\$(0.03)

**Common Shares:**

Full Diluted .....	404,254,263	295,596,151
Year-end .....	405,708,228	344,093,411

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....		2,466,578
Inventories .....		475,541
Current assets .....		4,179,468
Net property & equip. ....		202,926
Total assets .....		15,964,432
Liabilities:		
Current liabilities .....	2,384,045	
Long-term debt .....	2,627,912	
Stockholders' equity .....	10,952,475	
Net current assets .....	1,795,423	

**IRADIMED CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues .....	7,108,151	5,162,560
Cost & expenses .....	6,020,829	5,400,941
Operating income .....	1,087,322	(238,381)
Other income (expense), net .....	40,072	29,524
Net before taxes .....	1,127,394	(208,857)
Income taxes .....	286,198	24,483
<b>Net income</b> .....	<b>841,196</b>	<b>(233,340)</b>

**Earnings common share**

Primary .....	\$0.08	\$(0.02)
Fully Diluted .....	\$0.07	\$(0.02)

**Common Shares:**

Full Diluted .....	11,879,889	10,740,979
Year-end .....	10,622,042	10,749,895

**Consolidated Balance Sheet Items, as of (\$):**

Assets:		2018
Cash & equivalents .....		20,093,133
Inventories .....		4,308,321
Current assets .....		36,201,660
Net property & equip. ....		1,910,408
Total assets .....		40,260,737
Liabilities:		
Current liabilities .....	3,941,074	
Stockholders' equity .....	34,236,868	
Net current assets .....	32,260,586	

**ISRAMCO, INC.****Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016	2015
		(revised)	
Oil & gas sales revenues .....	43,890	40,409	42,198
Production services revenues .....	18,265	12,752	22,465
Office services revenues .....	554	569	634
Gains on divestiture .....	2,703	600	8,378
Other revenues .....	535	612	834
Total revenues .....	65,947	54,942	74,509
Lease operating expense, transportation & taxes .....	9,478	8,925	14,828
Depreciation, depletion &			

amortization	5,526	6,667	9,944	Accounts receivable, gross	14,980	12,196	Net Sales	03/30/18	03/31/17
Impairments of oil & gas assets & equipment	1,682	4,529	43,704	Allowance for doubtful accounts	2,431	2,294	Cost & expenses	159,942,000	167,591,000
Accretion expense	913	897	856	Accounts receivable, net	12,549	9,902	Operating income	7,312,000	7,602,000
Production services	18,241	14,494	21,802	Restricted & designated cash	802	701	Interest expense	8,027,000	8,366,000
Loss from plug & abandonment	26	(3)	91	Inventories	475	697	Other income (expense), net	171,000	256,000
General & administrative	5,455	5,366	6,140	Prepaid expenses & other current assets	2,711	2,295	Net before taxes	(544,000)	(508,000)
Total operating expenses	41,321	40,875	97,365	Total current assets	46,546	39,685	Income taxes	275,000	(15,000)
Operating income (loss)	24,626	14,067	(22,856)	Property & equipment, at cost - successful efforts	243,812	244,158	<b>Net income</b>	(819,000)	(493,000)
Interest expense, net	4,784	4,817	2,432	properties	243,812	244,158	Balance for common	(2,546,000)	(1,416,000)
Interest expense - related party, net	...	...	2,878	Property & equipment, at cost - successful efforts method - oil & gas	564	440	Earnings common share		
Gain (loss) from derivative contracts, net	(176)	(657)	(1,988)	for equipment	564	440	Primary	\$(0.09)	\$(0.05)
Capital gain (loss)	145	(70)	(85)	Other property, plant & equipment	59,108	57,292	Fully Diluted	\$(0.09)	\$(0.05)
Total other income (expenses)	(4,815)	(5,544)	(7,383)	Total property & equipment	303,484	301,890	Common Shares:		
Income (loss) before income taxes	(8,970)	(18,939)	(55,390)	equipment	303,484	301,890	Full Diluted	27,329,000	25,784,000
- U.S.	28,781	27,462	25,151	Accumulated depreciation, depletion, amortization & impairment	251,355	246,390	Year-end	27,374,458	...
Income (loss) before income taxes - foreign	19,811	8,523	(30,239)	Net property & equipment	52,129	55,500	<b>Consolidated Balance Sheet Items, as of (\$):</b>		
Current federal income tax expense (benefit)	(57)	...	...	Deferred tax assets & other assets	...	38,735	Assets:		2018
Current foreign income tax expense (benefit)	6,907	6,866	6,665	Derivative asset	187	...	Cash & equivalents	47,991,000	
Current state income tax expense (benefit)	...	...	69	Restricted cash - long term	9,674	7,122	Inventories	75,372,000	
Total current income tax expense (benefit)	6,850	6,866	6,734	Investments	261	230	Current assets	225,346,000	
Deferred federal income tax expense (benefit)	38,787	(3,232)	(15,985)	Total assets	108,797	141,272	Net property & equip.	151,693,000	
Total deferred income tax expense (benefit)	38,787	(3,232)	(15,985)	Accounts payable & accrued expenses	13,515	11,840	Total assets	563,791,000	
Income tax expense (benefit)	45,637	3,634	(9,251)	Short term debt & current maturities of long-term debt, net	18,517	9,147	Liabilities:		
<b>Net income (loss)</b>	(25,826)	4,889	(20,988)	Payables due to related party	60	90	Current liabilities	114,753,000	
Net loss (income) attributable to non-controlling interests	1,516	1,856	3,678	Accrued interest	1,027	974	Long-term debt	391,694,000	
Net income (loss) attributable to Isramco, Inc.	(24,310)	6,745	(17,310)	Derivative liability	457	916	Stockholders' equity	9,515,000	
Weighted average shares outstanding - basic	2,718	2,718	2,718	Total current liabilities	33,576	22,967	Net current assets	110,593,000	
Weighted average shares outstanding - diluted	2,718	2,718	2,718	Bank loan, principal	98,400	108,000	<b>JERASH HOLDINGS (US) INC</b>		
Year end shares outstanding	2,718	2,718	2,718	Less: unamortized discount & debt costs	(2,959)	(3,748)	<b>Earnings, 6 mos. to Sep 30 (Consol. - \$):</b>		
Earnings (loss) per share - basic	\$(8.95)	\$2.48	\$(6.37)	Total long-term debt	95,441	104,252	2017	2016	
Earnings (loss) per share - diluted	\$(8.95)	\$2.48	\$(6.37)	Less: current maturities & current discount	18,072	8,811	Total revenues	48,899,637	37,322,614
Number of full time employees	193	170	224	Long-term debt	77,369	95,441	Cost & expenses	39,707,906	31,745,188
Number of common shareholders	139	155	189	Asset retirement obligations	21,670	20,748	Operating income	9,191,731	5,577,426
				Derivative liability	...	100	Other income (expense), net	(10,928)	(24,431)
				Total liabilities	132,615	139,256	<b>Net income</b>	9,180,803	5,552,995
				Common stock	27	27	Earnings common share		
				Additional paid-in capital	23,853	23,853	Primary	\$0.96	\$0.63
				Retained earnings (accumulated deficit)	(40,970)	(16,660)	Fully Diluted	\$0.95	\$0.63
				Treasury stock, at cost	164	164	Common Shares:		
				Total Isramco, Inc. shareholders' equity	(17,254)	7,056	Full Diluted	9,577,172	8,787,500
				Non-controlling interest	(6,564)	(5,040)	Year-end	9,895,000	8,787,500
				Total equity (deficit)	(23,818)	2,016	<b>KERYX BIOPHARMACEUTICALS INC.</b>		
							<b>Earnings, 3 mos. to Mar 31 (Consol. - \$):</b>		
							2018	2017	
							Total revenues	21,751,000	11,819,000
							Cost & expenses	44,503,000	34,929,000
							Operating income	(22,752,000)	(23,110,000)
							Interest income	201,000	117,000
							Other income (expense), net	21,000	(3,000)
							Net before taxes	(22,530,000)	(22,996,000)
							Income taxes	(634,000)	20,000
							<b>Net income</b>	(21,896,000)	(23,016,000)
							Earnings common share		
							Primary	\$(0.18)	\$(0.21)
							Fully Diluted	\$(0.18)	\$(0.21)
							Common Shares:		
							Full Diluted	119,844,320	107,071,634
							Year-end	120,451,373	107,682,142
							<b>Consolidated Balance Sheet Items, as of (\$):</b>		
							Assets:		2018
							Cash & equivalents	60,087,000	
							Inventories	35,443,000	
							Current assets	119,549,000	
							Net property & equip.	4,347,000	
							Total assets	140,122,000	
							Liabilities:		
							Current liabilities	44,918,000	
							Long-term debt	125,000,000	
							Stockholders' equity	(31,608,000)	
							Net current assets	74,631,000	
							<b>KINDRED BIOSCIENCES INC</b>		
							<b>Earnings, 3 mos. to Mar 31 (Consol. - \$000):</b>		
							2018	2017	
							Cost & expenses	10,248	6,623
							Operating income	(10,248)	(6,623)
							<b>Net income</b>	(9,971)	(6,492)
							Earnings common share		
							Primary	\$(0.36)	\$(0.30)
							Fully Diluted	\$(0.36)	\$(0.30)
							Common Shares:		

□ As is; □ Approximately; □ As of March 12, 2018; □ As of March 10, 2017; □ As of March 11, 2016

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**  
2017  
□2016 (revised)

Cash & cash equivalents 30,009 26,090

□ Reclassified to conform with 2017 presentation; □ Net of discount: \$828,000; □ Net of discount: \$789,000; □ Net of discount: \$2,131,000; □ Net of discount: \$2,959,000

**Recent Dividends:**  
**1. Isramco, Inc. common.**  
No dividends paid.

**Annual Dividends:**  
**1. Isramco, Inc. common.**  
No dividends paid.

**JASMIN CORP**  
**New Accountant** On Jan. 11, 2018, Co. dismissed Pritchett, Siler & Hardy, P.C. as its independent public accounting firm. On Jan. 23, 2018, Co. engaged Haynie & Company as its new independent public accounting firm.

**JASON INDUSTRIES INC**  
**Earnings, 3 mos. to (Consol. - \$):**

2018 2017  
Operating income (10,248) (6,623)  
Net income (9,971) (6,492)  
Earnings common share  
Primary \$(0.36) \$(0.30)  
Fully Diluted \$(0.36) \$(0.30)  
Common Shares:

Full Diluted	27,986	21,516
Year-end	28,197	23,179
<b>Consolidated Balance Sheet Items, as of (\$000):</b>		
Assets:		
Cash & equivalents	44,496	2018
Current assets	72,207	72,207
Net property & equip.	7,907	7,907
Total assets	80,167	80,167
Liabilities:		
Current liabilities	3,899	3,899
Stockholders' equity	76,157	76,157
Net current assets	68,308	68,308

**KINERJAPAY CORP**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	3,305,574	1,260,465
Operating income	(3,317,922)	(1,259,580)
Other income (expense), net	(39,656)	
Net before taxes	(3,367,235)	(1,259,580)
<b>Net income</b>	(3,367,235)	(1,259,580)
Earnings common share		
Primary	\$(0.23)	\$(0.14)
Fully Diluted	\$(0.23)	\$(0.14)
Common Shares:		
Full Diluted	14,423,855	9,114,235
Year-end	14,642,207	9,727,013

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	310,462	2018
Inventories	16,105	16,105
Current assets	417,440	417,440
Net property & equip.	14,045	14,045
Total assets	560,061	560,061
Liabilities:		
Current liabilities	866,789	866,789
Stockholders' equity	(306,728)	(306,728)
Net current assets	(449,349)	(449,349)

**LA JOLLA PHARMACEUTICAL CO.**

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total revenues	809	809
Cost & expenses	51,503	23,268
Operating income	(50,694)	(23,268)
Other income (expense), net	166	28
<b>Net income</b>	(50,528)	(23,240)
Earnings common share		
Primary	\$(2.22)	\$(1.26)
Fully Diluted	\$(2.22)	\$(1.26)
Common Shares:		
Full Diluted	22,742	18,410
Year-end	26,154	22,123

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	154,408	2018
Inventories	820	820
Current assets	161,554	161,554
Net property & equip.	24,438	24,438
Total assets	186,901	186,901
Liabilities:		
Current liabilities	16,015	16,015
Stockholders' equity	157,413	157,413
Net current assets	145,539	145,539

**LANTRONIX INC.**

Earnings, 9 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total revenues	33,543	33,686
Cost & expenses	33,372	33,683
Operating income	33	(163)
Other income (expense), net	1	3
Net before taxes	20	(178)
Income taxes	92	47
<b>Net income</b>	(72)	(225)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	18,050	17,374
Year-end	18,248	17,587

**LEO MOTORS INC**

**New Accountant** On May 17, 2018, Co. engaged Turner, Stone & Company, LLP as its new independent public accounting firm.

**LEXARIA BIOSCIENCE CORP**

**Wrts. Exercise Terms** On May 23, 2018, Co. announced that it has received US\$24,500 from the exercise of warrants previously granted. Co. has received for exercise a total of 175,000 warrants with an exercise price of US\$0.14, previously granted. The warrant exercises are by a third party who is neither an officer nor a director of Co. No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.

**LINDBLAD EXPEDITIONS HOLDINGS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	62,994,000	58,000,000
Operating income	14,371,000	1,365,000
Other income (expense), net	8,000	(263,000)
Gains or losses	(451,000)	246,000
Net before taxes	11,194,000	(967,000)
Income taxes	277,000	(1,592,000)
<b>Net income</b>	10,917,000	625,000
Earnings common share		
Primary	\$0.24	\$0.01
Fully Diluted	\$0.24	\$0.01
Common Shares:		
Full Diluted	45,667,565	45,761,938
Year-end	45,357,640	45,138,691

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	97,284,000	2018
Inventories	1,826,000	1,826,000
Current assets	147,421,000	147,421,000
Net property & equip.	260,804,000	260,804,000
Total assets	448,799,000	448,799,000
Liabilities:		
Current liabilities	137,461,000	137,461,000
Long-term debt	188,481,000	188,481,000
Stockholders' equity	112,951,000	112,951,000
Net current assets	9,960,000	9,960,000

**LIPOCINE INC (NEW)**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total revenues	428,031	428,031
Cost & expenses	3,065,017	4,908,915
Operating income	(2,636,986)	(4,908,915)
Interest expense	192,466	192,466
Net before taxes	(2,719,271)	(4,860,560)
Income taxes	700	700
<b>Net income</b>	(2,719,971)	(4,861,260)
Earnings common share		
Primary	\$(0.13)	\$(0.26)
Fully Diluted	\$(0.13)	\$(0.26)
Common Shares:		
Full Diluted	21,264,539	18,711,239
Year-end	21,264,539	19,261,742

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	8,561,313	2018
Current assets	31,624,564	31,624,564
Net property & equip.	32,331	32,331
Total assets	31,680,648	31,680,648
Liabilities:		
Current liabilities	6,283,934	6,283,934
Long-term debt	8,724,452	8,724,452
Stockholders' equity	16,672,262	16,672,262
Net current assets	25,340,630	25,340,630

**LIVEPERSON INC**

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total revenues	58,241	50,919
Cost & expenses	61,638	55,371
Operating income	(3,821)	(4,924)
Other income (expense), net	129	320
Net before taxes	(3,692)	(4,604)
Income taxes	(489)	1,072
<b>Net income</b>	(3,203)	(5,676)
Earnings common share		
Primary	\$(0.06)	\$(0.10)
Fully Diluted	\$(0.06)	\$(0.10)
Common Shares:		

Full Diluted	57,310	55,975
Year-end	60,538	58,421

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	57,480	2018
Current assets	116,787	116,787
Net property & equip.	36,328	36,328
Total assets	249,060	249,060
Liabilities:		
Current liabilities	96,187	96,187
Stockholders' equity	146,117	146,117
Net current assets	20,600	20,600

**MARIJUANA COMPANY OF AMERICA INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Net Sales	19,010	5,893
Cost & expenses	311,925	17,982,103
Operating income	(294,308)	(17,976,452)
Interest expense	730,746	121,721
Other income (expense), net	5,175,852	19,889
Net before taxes	4,150,799	(18,078,284)
<b>Net income</b>	4,150,799	(18,078,284)
Earnings common share		
Primary	\$0.00	\$(0.01)
Fully Diluted	\$0.00	\$(0.01)
Common Shares:		
Full Diluted	3,113,338,017	676,904,069
Year-end	2,139,307,875	984,042,453

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	170,085	2018
Inventories	228,930	228,930
Current assets	402,728	402,728
Net property & equip.	16,377	16,377
Total assets	1,079,409	1,079,409
Liabilities:		
Current liabilities	4,878,362	4,878,362
Long-term debt	101,898	101,898
Stockholders' equity	(4,777,411)	(4,777,411)
Net current assets	(4,475,634)	(4,475,634)

**MARINA BIOTECH INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	1,093,164	868,875
Operating income	(1,216,425)	(967,253)
Other income (expense), net		(103,072)
Net before taxes	(1,361,169)	(1,081,978)
Income taxes		800
<b>Net income</b>	(1,361,169)	(1,082,778)
Earnings common share		
Primary	\$(0.13)	\$(0.12)
Fully Diluted	\$(0.13)	\$(0.12)
Common Shares:		
Full Diluted	10,521,278	9,407,340
Year-end	10,521,728	9,709,988

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	47,768	2018
Current assets	146,904	146,904
Total assets	6,082,446	6,082,446
Liabilities:		
Current liabilities	6,876,493	6,876,493
Stockholders' equity	(794,047)	(794,047)
Net current assets	(6,729,589)	(6,729,589)

**MATLIN & PARTNERS ACQUISITION CORP**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	207,610	99,910
Operating income	(207,610)	(99,910)
Interest income	1,106,088	74,631
Net before taxes	898,478	(25,279)
Income taxes	221,778	
<b>Net income</b>	676,700	(25,279)
Earnings common share		
Primary	\$0.07	\$(0.02)
Fully Diluted	\$0.02	\$(0.02)
Common Shares:		
Full Diluted	40,625,000	8,796,089
Year-end	9,387,022	9,532,975

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	482,694
Current assets	561,979
Total assets	327,821,676
Liabilities:	
Current liabilities	191,888
Stockholders' equity	5,000,008
Net current assets	370,091

**MEDGEN INC****Earnings, 3 mos. to Dec 31(Consol. - \$):**

	2017	2016
Operating income	(2,654)	
Interest expense	17,190	614
Gains or losses	2,654	
<b>Net income</b>	<b>(14,536)</b>	<b>(614)</b>
Earnings common share		
Common Shares:		
Full Diluted	2,867,814,753	867,814,753
Year-end	575,563	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2017
Liabilities:	
Current liabilities	753,179
Stockholders' equity	(753,179)
Net current assets	(753,179)

**MEET GROUP INC (THE)****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	37,637,793	20,058,797
Cost & expenses	37,968,659	17,925,858
Operating income	(3,960,469)	448,100
Interest income	7,208	2,570
Interest expense	607,686	2,332
Other income (expense), net	(6,944)	
Net before taxes	(4,464,848)	446,138
Income taxes	(252,187)	292
<b>Net income</b>	<b>(4,212,661)</b>	<b>445,846</b>
Earnings common share		
Primary	\$(0.06)	\$0.01
Fully Diluted	\$(0.06)	\$0.01
Common Shares:		
Full Diluted	71,981,487	66,204,620
Year-end	71,106,997	68,970,772

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	27,969,456
Current assets	51,752,305
Net property & equip.	4,149,034
Total assets	272,552,144
Liabilities:	
Current liabilities	46,988,146
Long-term debt	37,130,998
Stockholders' equity	183,806,071
Net current assets	4,764,159

**MERIT MEDICAL SYSTEMS, INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	203,035,000	171,069,000
Cost & expenses	194,254,000	165,460,000
Operating income	8,781,000	5,609,000
Interest income	146,000	83,000
Interest expense	2,398,000	2,706,000
Other income (expense), net	(170,000)	264,000
Gains or losses		12,243,000
Net before taxes	6,359,000	15,493,000
Income taxes	1,090,000	690,000
<b>Net income</b>	<b>5,269,000</b>	<b>14,803,000</b>
Earnings common share		
Primary	\$0.10	\$0.33
Fully Diluted	\$0.10	\$0.32
Common Shares:		
Full Diluted	51,910,000	45,820,000
Year-end	50,346,000	49,891,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	34,171,000
Inventories	166,716,000
Current assets	343,770,000
Net property & equip.	303,725,000
Total assets	1,239,209,000

Liabilities:	
Current liabilities	124,400,000
Long-term debt	365,797,000
Stockholders' equity	688,511,000
Net current assets	219,370,000

**MICRONET ENERTEC TECHNOLOGIES INC**

**Ironet Sale Completed** On May 22, 2018, Co., through its wholly-owned subsidiary, Enertec Management Ltd., sold all the outstanding equity of its wholly-owned aerospace and defense subsidiary, Enertec Systems 2001 Ltd. ("Enertec Systems"), to DPW Holdings, Inc. ("DPW") wholly-owned subsidiary, Coolisys Technologies Inc. ("Buyer"), for an aggregate gross proceeds of approximately \$4,700,000, of which 10% was held in escrow for up to 14 months after the Closing to satisfy certain potential indemnification claims. The final consideration amount was adjusted, pursuant to the terms of the Share Purchase Agreement, as a result of adjustments relating to certain Enertec Systems' debts at the Closing. In addition, Buyer also assumed approximately \$4,000,000 of Enertec Systems' debt. Co.'s pro forma capital gain from the sale of Enertec Systems, based on Co.'s balance sheet as of Mar. 31, 2018 was approximately \$4,500,000. In addition, Co., Enertec Systems, the Buyer, DPW and Mr. David Lucatz, Co.'s Chief Executive Officer, executed a consulting agreement (the "Consulting Agreement") whereby Micronet, via Mr. Lucatz, would provide Enertec Systems with certain consulting and transitional services over a 3 year period as necessary and requested by the Buyer (but in no event to exceed 20% of Mr. Lucatz's time). The Buyer (via Enertec Systems) would pay Co. an annual consulting fee of \$150,000 as well as issue Co. 150,000 restricted shares of DPW Class A common stock (the "DPW Equity") for such services, to be vested and released from restriction in three equal installments, with the initial installment vesting the day after the Closing and the remaining installments vesting on each of the first 2 anniversaries of the Closing. In the event of a change of control in Co., or if Mr. Lucatz shall no longer be employed by Co., the rights and obligations under the Consulting Agreement shall be assigned to Mr. Lucatz along with the DPW Equity.

**MINERCO INC**

**Acquisition Completed** On May 23, 2018, Co. acquired controlling interest in Priwen Systems Inc., a Cryptocurrency Mining and Technology company. Terms of the transaction were not disclosed.

**MIRAGEN THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	4,784,000	462,000
Cost & expenses	9,403,000	7,401,000
Operating income	(4,619,000)	(6,939,000)
<b>Net income</b>	<b>(4,661,000)</b>	<b>(6,980,000)</b>
Balance for common	(4,661,000)	(6,985,000)
Earnings common share		
Primary	\$(0.18)	\$(0.60)
Fully Diluted	\$(0.18)	\$(0.60)
Common Shares:		
Full Diluted	26,483,112	11,555,286
Year-end	30,186,540	21,401,828

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	78,099,000
Current assets	86,353,000
Net property & equip.	589,000
Total assets	86,992,000
Liabilities:	
Current liabilities	4,137,000
Long-term debt	10,018,000
Stockholders' equity	72,706,000
Net current assets	82,216,000

**MIRATI THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues	9,467	
Cost & expenses	24,813	18,090
Operating income	(15,346)	(18,090)
Other income (expense), net	637	244
<b>Net income</b>	<b>(14,709)</b>	<b>(17,846)</b>
Earnings common share		
Primary	\$(0.51)	\$(0.73)
Fully Diluted	\$(0.51)	\$(0.73)
Common Shares:		
Full Diluted	28,844	24,384
Year-end	29,026	24,940

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018
Cash & equivalents	20,567
Current assets	153,073
Net property & equip.	484
Total assets	154,544
Liabilities:	
Current liabilities	16,010
Stockholders' equity	137,841
Net current assets	137,063

**MITEK SYSTEMS, INC.**

**Acquisition Completed** On May 23, 2018, Co. acquired all the issued and outstanding shares of A2iA Group II, S.A.S. ("A2iA"), a simplified joint stock company formed under the laws of France and engaged in artificial intelligence (AI) and image analysis, from the holders of outstanding shares of A2iA (the "Sellers") for an aggregate purchase price of Euro42,500,000, comprised of: (i) a cash payment to Sellers of Euro24,400,000, subject to adjustments for change in control payments, transaction expenses, indebtedness and net working capital (the "Cash Payment"); and (ii) the issuance to Sellers of approximately Euro18,100,000 in shares of Co.'s common stock ("Closing Shares"), par value \$0.001 per share ("Common Stock"), calculated based on the average closing price per share of Common Stock as reported on the NASDAQ Global Market for the 20 trading days prior to the day immediately preceding the Closing Date. Co. deposited Euro590,000 of the Cash Payment and Euro3,660,000 of Closing Shares into an escrow fund to serve as collateral and partial security for certain indemnification rights of Co. The escrow fund would be maintained for up to 24 months following the completion of the Acquisition or until such earlier time as the escrow fund is exhausted. As the result, A2iA became a wholly-owned subsidiary of Co.

**MITEK SYSTEMS, INC.****Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	26,413,000	20,688,000
Cost & expenses	29,990,000	20,136,000
Operating income	(3,577,000)	552,000
Other income (expense), net	394,000	132,000
Net before taxes	(3,183,000)	684,000
Income taxes	3,713,000	74,000
<b>Net income</b>	<b>(6,896,000)</b>	<b>610,000</b>
Earnings common share		
Primary	\$(0.20)	\$0.02
Fully Diluted	\$(0.20)	\$0.02
Common Shares:		
Full Diluted	34,976,000	34,818,392
Year-end	35,058,864	33,324,328

**MUSIC OF YOUR LIFE INC**

**Stock Split Development** On May 18, 2018, Co.'s board of directors and holders of a majority in interest of Co.'s voting capital stock approved a 1-for-4,000 reverse split of our common shares ("Reverse Split"). This approval is anticipated to be effective 20 days after this Information Statement has been distributed to Co. shareholders. As a result of the Reverse Split, each shareholder of record as of May 18, 2018, will receive one (1) share of common stock for each four thousand (4,000) shares of common stock they held prior to the Reverse Split, provided however, that fractions of a share shall be rounded up to the nearest whole share. Co.'s board of directors believes that the Reverse Split is advisable and in the best interests of Co. and its stockholders to allow Co. to execute a new business plan and position itself to raise additional investment capital, if needed.

**MYDX INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	76,429	85,391
Cost & expenses	557,328	812,204
Operating income	(480,899)	(726,813)
Interest expense	8,751	270,006
Other income (expense), net	1,369,555	(4,103,453)
Net before taxes	879,905	(5,100,272)
<b>Net income</b>	<b>879,905</b>	<b>(5,100,272)</b>
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	5,320,872,536	120,023,451
Year-end	1,894,397,541	546,329,348

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	37,590
Inventories	170,432
Current assets	208,022
Net property & equip.	47,939
Total assets	420,085
Liabilities:	
Current liabilities	3,671,926
Stockholders' equity	(8,897,664)
Net current assets	(3,463,904)

**NATE'S FOODS CO**

Earnings, 6 mos. to Nov 30(Consol. - \$):

	2017	2016
Cost & expenses	46,860	113,113
Operating income	(44,235)	(129,481)
Interest expense	18,586	185,575
Other income (expense), net	(259,330)	1,415,392
Net income	(322,151)	1,100,336
Balance for common	(322,151)	1,099,802
Earnings common share		
Common Shares:		
Full Diluted	475,217,137	665,215,644
Year-end	507,669,616	331,721,856

**NEOGENOMICS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total revenues	63,423,000	57,428,000
Cost & expenses	60,918,000	58,008,000
Operating income	2,505,000	(580,000)
Interest expense	1,486,000	1,364,000
Other income (expense), net	63,000	
Net before taxes	1,082,000	(1,944,000)
Income taxes	438,000	(779,000)
Net income	644,000	(1,165,000)
Balance for common	(2,212,000)	(3,731,000)
Earnings common share		
Primary	\$(0.03)	\$(0.05)
Fully Diluted	\$(0.03)	\$(0.05)
Common Shares:		
Full Diluted	80,507,000	78,650,000
Year-end	80,568,453	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	15,173,000
Inventories	7,515,000
Current assets	87,771,000
Net property & equip.	40,411,000
Total assets	349,272,000
Liabilities:	
Current liabilities	43,303,000
Long-term debt	90,837,000
Stockholders' equity	172,545,000
Net current assets	44,468,000

**NETLIST INC**

Earnings, 3 mos. to (Consol. - \$000):

	03/31/18	04/01/17
Net Sales	8,879	9,426
Cost & expenses	13,410	12,622
Operating income	(4,531)	(3,196)
Other income (expense), net	5	2
Net before taxes	(4,673)	(3,342)
Net income	(4,673)	(3,342)
Earnings common share		
Primary	\$(0.06)	\$(0.05)
Fully Diluted	\$(0.06)	\$(0.05)
Common Shares:		
Full Diluted	82,461	61,681
Year-end	85,415	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	6,912
Inventories	3,407
Current assets	14,971
Net property & equip.	426
Total assets	16,796
Liabilities:	
Current liabilities	9,802
Long-term debt	14,895
Stockholders' equity	(7,964)
Net current assets	5,169

**NEW JERSEY MINING CO.**

**Interest Sale Completed** On May 18, 2018, Co. sold its Toboggan project, which was comprised of the surface rights to the Little Baldy patented claims, 106 unpatented mining claims and information and data associated with the claims, to Hecla Mining Company wholly-owned subsidiary, Hecla Silver Valley, Inc. ("Hecla"), for \$3,000,000. Co. retained a 2% Net Smelter Return Royalty on production from the Toboggan property, of which Hecla has the right to buy back 1% for \$1,000,000. In addition, in connection with the transactions Hecla purchased certain equity securities of Co. for an aggregate purchase price of \$500,000.

**NEXEO SOLUTIONS INC**

Earnings, 6 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	1,912,800,000	702,100,000
Operating income	57,800,000	10,400,000
Interest income	200,000	200,000
Interest expense	25,700,000	24,500,000
Other income (expense), net	500,000	2,600,000
Net before taxes	32,800,000	(11,300,000)
Income taxes	5,900,000	(1,900,000)
Net income	26,900,000	(9,400,000)
Earnings common share		
Primary	\$0.35	\$(0.12)
Fully Diluted	\$0.35	\$(0.12)
Common Shares:		
Full Diluted	77,209,536	76,746,168
Year-end	89,741,309	89,276,183

**NEXEON MEDSYSTEMS INC**

**Stock Split Development** On May 14, 2018, the holders of a majority of Co.'s outstanding voting capital as of the Record Date approved, by written consent pursuant to Section 78.320 of the Nevada Revised Statutes and the Company's bylaws, the following action (theAction): To permit, but not require, the Board of Directors of Co. to effectuate a reverse stock split of Co.'s common stock, par value \$0.001 per share by a ratio of not less than one (1) for two (2) and not more than one (1) for twenty-five (25) (theRange), with the exact ratio to be set at a whole number within this Range as determined by the Board in its sole discretion within one year of the Record Date.

**NI HOLDINGS INC**

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total revenues	38,327	34,915
Cost & expenses	23,687	22,875
Operating income	7,601	7,031
Net before taxes	7,601	7,031
Income taxes	1,449	2,282
Net income	6,152	4,749
Earnings common share		
Primary	\$0.27	\$0.21
Fully Diluted	\$0.27	\$0.21
Common Shares:		
Full Diluted	22,362	22,760
Year-end	22,353	22,760

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	25,209
Current assets	57,132
Net property & equip.	5,879
Total assets	376,124
Liabilities:	
Current liabilities	1,079
Stockholders' equity	258,649
Net current assets	56,053

**NORTH BAY RESOURCES INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	59,350	59,544
Operating income	(59,350)	(59,544)
Other income (expense), net	2,742	5,069
Gains or losses		4,236
Net income	(56,608)	(50,239)
Earnings common share		
Common Shares:		
Full Diluted	2,044,001,404,565,362,098	
Year-end	2,777,829,451	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	71
Current assets	71
Total assets	34,491

**Liabilities:**

Current liabilities	3,141,579
Stockholders' equity	(3,107,088)
Net current assets	(3,141,508)

**NORTHERN MINERALS & EXPLORATION LTD.**

Earnings, 3 mos. to Oct 31(Consol. - \$):

	2017	2016
Total revenues	11,292	
Cost & expenses	101,538	60,474
Operating income	(90,246)	(60,474)
Interest expense	7,184	19,351
Gains or losses		(470,469)
Net before taxes	(97,430)	(550,294)
Net income	(97,430)	(550,294)

Earnings common share

Primary	\$(0.02)	\$(0.02)
Fully Diluted	\$(0.02)	\$(0.02)
Common Shares:		
Full Diluted	28,662,202	26,461,405
Year-end	37,297,818	26,497,818

Consolidated Balance Sheet Items, as of (\$):

Assets:	2017
Cash & equivalents	35,191
Current assets	45,191
Net property & equip.	126,065
Total assets	171,256
Liabilities:	
Current liabilities	500,259
Stockholders' equity	(329,003)
Net current assets	(455,068)

**NORTHSIGHT CAPITAL INC**

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total revenues	12,763	3,165
Cost & expenses	526,789	187,598
Operating income	(514,026)	(184,433)
Interest expense	32,628	17,323
Other income (expense), net	64,431	
Net income	(482,223)	(201,756)
Earnings common share		
Common Shares:		
Full Diluted	129,493,891	113,188,229
Year-end	130,578,741	113,236,581

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	2,419
Current assets	220,227
Total assets	1,051,343
Liabilities:	
Current liabilities	3,506,630
Long-term debt	468,013
Stockholders' equity	(2,923,300)
Net current assets	(3,286,403)

**NV5 GLOBAL INC**

Earnings, 3 mos. to (Consol. - \$000):

	03/31/18	04/01/17
Total revenues	94,534	64,059
Cost & expenses	84,437	59,037
Deprec., depl. & amort.	3,796	2,501
Operating income	6,301	2,521
Interest expense	611	239
Net before taxes	5,690	2,282
Income taxes	1,398	12
Net income	4,292	2,270
Earnings common share		
Primary	\$0.42	\$0.23
Fully Diluted	\$0.39	\$0.21
Common Shares:		
Full Diluted	10,913	10,719
Year-end	10,991	10,588

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	17,202
Current assets	133,696
Net property & equip.	9,975
Total assets	313,029
Liabilities:	
Current liabilities	54,306
Long-term debt	58,967
Stockholders' equity	187,022
Net current assets	79,390

**OMPHALOS CORP****Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2018	2017
Net Sales	154,541	204,016
Cost & expenses	198,607	271,817
Operating income	(44,066)	(67,801)
Interest expense	7,684	7,253
Foreign currency	(2,035)	10,615
Net before taxes	(53,785)	(64,439)
<b>Net income</b>	<b>(53,785)</b>	<b>(64,439)</b>
Earnings common share		
Common Shares:		
Full Diluted	30,063,759	30,063,759
Year-end	30,063,759	30,063,759

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	48,241	
Inventories	140,360	
Current assets	282,691	
Net property & equip.	6,455	
Total assets	308,380	
Liabilities:		
Current liabilities	1,387,174	
Long-term debt	515,464	
Stockholders' equity	(1,594,258)	
Net current assets	(1,104,483)	

**ONE HORIZON GROUP INC**

**Acquisition Completed** On May 18, 2018, Co. acquired 51% of the outstanding shares of the capital stock of Banana Whale Studios Pte. Ltd. ("Banana Whale"), a B2B software provider in the \$100+ billion-dollar gaming industry focusing on innovation and next generation games and entertainment, from Banana Whale stockholders in exchange Co. agreed to issue to Banana Whale stockholders the number of shares of Co. common stock determined by dividing six times the net after tax earnings of Banana Whale during the twenty-four month period ending May 31, 2020, (the "Measurement Period") by the average of the closing price of Co. common stock during the ten trading days immediately preceding the end of the Measurement Period (the "Market Value"). If Banana Whale's net after tax earnings during the Measurement Period exceeds \$5,655,000, Co. would issue to the stockholders of Banana Whale a number of additional shares of common stock equal to Banana Whale's net after-tax earnings for the Measurement Period, divided by the Market Value of the common stock; provided, that if Banana Whale's net after tax earnings during the Measurement Period exceeds \$5,655,000 by more than 20%, Co. would deliver to the stockholders of Banana Whale a number of additional shares of common stock equal to two (2) times Banana Whale's net after-tax earnings for the Measurement Period, divided by the Market Value of the common stock. To the extent the number of shares which Co. was obligated to issue to the stockholders of Banana Whale exceeds 19.99% of Co. outstanding shares of common stock, stockholder approval for issuance of those shares is required under applicable rules of NASDAQ. As a condition to closing the acquisition, Banana Whale's stockholders demanded and Co. agreed to issue to them 7,383,000 shares of Co. common stock as security for Co. obligation to issue such shares to which they may become entitled. If the number of shares to which the stockholders of Banana Whale become entitled is less than 7,383,000, the excess shares will be returned to Co. for cancellation.

**OPTEC INTERNATIONAL INC****Earnings, 9 mos. to Mar 31**(Consol. - \$):

	2018	2017
Total revenues	91,105	24,200
Cost & expenses	176,571	21,103
Operating income	(88,523)	40
Other income (expense), net	(574,511)	
<b>Net income</b>	<b>(802,854)</b>	<b>40</b>
Earnings common share		
Primary	\$(0.01)	\$
Fully Diluted	\$(0.01)	\$
Common Shares:		
Full Diluted	31,051,799	52,944,500
Year-end	19,245,000	52,944,500

**OPTILEAF INC****Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2018	2017
Net Sales	5,234	7,451
Cost & expenses	49,868	58,073
Operating income	(44,634)	(50,622)
Interest income		21

Net before taxes	(44,634)	(50,601)
<b>Net income</b>	<b>(44,634)</b>	<b>(50,601)</b>
Earnings common share		
Common Shares:		
Full Diluted	21,443,752	19,210,419
Year-end	21,433,752	20,210,419

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	20,364	
Inventories	6,197	
Current assets	27,061	
Total assets	30,460	
Liabilities:		
Current liabilities	23,852	
Long-term debt	45,000	
Stockholders' equity	(38,393)	
Net current assets	3,209	

**OREXIGEN THERAPEUTICS INC**

**Bankruptcy Proceedings** On May 21, 2018, the U.S. Bankruptcy Court issued an order approving Co.'s motion to authorize the Debtor's motion for authority to provide an advance payment to Syneos Health and its affiliates. As previously reported, "By this Motion, the Debtor seeks entry of an order authorizing the Debtor to provide the Advance Payment to Syneos in the amount of \$356,525 on account of the Second Quarter Bonus and payroll taxes associated therewith. Post-petition, in Aug. or Sept. 2018, the Bonus for the second quarter of 2018 will become due and payable by Syneos to the Sales Representatives in the estimated total amount of \$325,000 (the 'Second Quarter Bonus'). The Second Quarter Bonus is calculated based on an agreed upon target bonus amount of \$6,500.00 for each of the fifty Sales Representatives currently providing services to Co. Additionally, Syneos will incur payroll taxes at the rate of 9.7%, in the approximate amount of \$31,525. Accordingly, the total amount which Syneos expects to disburse on account of the Second Quarter Bonus is \$356,525 (the 'Advance Payment')." Also on May 21, 2018, The U.S. Bankruptcy Court issued an order approving Co.'s motion for entry of an order authorizing the Debtor to enter into a stipulation with McKesson Corporation and McKesson Patient Relationship Solutions, a business unit of McKesson Specialty Arizona (MPRS) with respect to the McKesson Prepetition distribution agreement receivable and the MPRS prepetition claim. As previously reported, "MPRS asserts that it holds a prepetition claim against the Debtor in the amount of approximately \$8,500,000 (the 'MPRS Prepetition Claim') under the LoyaltyScript Agreement, and the Debtor reserves all rights and defenses whether arising in law or equity with respect to the MPRS Prepetition Claim. Within 3 business days of the entry of an Order approving the Stipulation, McKesson shall make a payment (by wire or other electronic means), to the Debtor on account of any prepetition amounts withheld under the McKesson Prepetition Distribution Agreement Receivable, which is currently estimated to be in the amount of \$3,666,560.64, which McKesson and the Debtor agree will be applied to the McKesson Prepetition Distribution Agreement Receivable subject to any reconciliation by the Parties for facts not known at the time of the Stipulation."

**OREXIGEN THERAPEUTICS INC**

**Bankruptcy Proceedings** On May 24, 2018, the U.S. Bankruptcy Court scheduled a May 24, 2018 hearing to consider Co.'s stipulation.

**OREXIGEN THERAPEUTICS INC**

**Bankruptcy Proceedings** On May 25, 2018, the U.S. Bankruptcy Court issued an order approving Co.'s motion for authority to enter into a stipulation with Cardinal Health and Cardinal Health 105. As previously reported, "Cardinal Health owes the Debtor a total of \$5,100,696.04 under the WPA (the 'Debtor's Net WPA Claim'). Around Dec. 2017, certain third-party customers made payments to the Debtor totaling \$11,082,868.33 for Product sold under the Title Model Addendum (the 'TMA Payment'), which Cardinal Health 105 argues should have been paid to it. In connection with this dispute, the Debtor and Cardinal Health 105 entered into the Letter Agreement, whereby the Debtor agreed to certain modified payment terms with respect to the TMA Payment. In accordance with the Letter Agreement, the Debtor made a payment totaling \$5,541,434.17 to Cardinal Health 105. However, the Debtor did not pay the remainder of the TMA Payment before the Petition Date, and a total of \$5,541,434.17 remains outstanding ('Cardinal Health 105's TMA Claim')." The stipulation further settles, "The Stipulation accomplishes several goals shared by the Parties. Among other things, approval of the Stipulation will result in the estate's immediate realization of \$2,500,000 of the Debtor's Net WPA Claim, provides an expeditious process for resolving the dispute between the Parties, and guarantees that the

Parties will continue to honor their respective postpetition obligations. More specifically, the Stipulation states that, within three (3) business days of the entry of an Order approving the Stipulation, Cardinal Health shall make a payment of \$2,500,000 to the Debtor on account of the Debtor's Net WPA Claim."

**ORION HEALTHCORP INC**

**Bankruptcy Proceedings** On May 22, 2018, GSS Infotech filed with the U.S. Bankruptcy Court an objection to Co.'s motion for sale of property. The objection asserts, "GSS files this Objection to address the Debtor's attempt, through an inferior and financially unsupported sale, to sell substantially all of the Debtors' assets at a price and subject to terms that will not realize the total value of the Debtors' assets, subject to the Sale of assets withheld for future treatment or sale by the Debtors. Furthermore, the Debtors' proposed Sale will have the sole effect of substantially increasing Administrative Expenses in this Chapter 11 Case for the benefit of the Debtors' retained professionals and both prepetition and post-petition secured lenders."

**ORION HEALTHCORP INC**

**Bankruptcy Proceedings** On May 21, 2018, Co. filed with the U.S. Bankruptcy Court a monthly operating report for Mar. 16, 2018 to Apr. 30, 2018. For the period, the consolidated Debtors reported a \$1,600,000 net loss on zero total revenue and \$95,000 in professional & consulting fees. Total Debtors' cash at the beginning of the period was \$439,000 and \$3,300,000 at the period's end, with net cash flow of \$2,900,000. Consolidated Debtors also reported cash disbursements of \$2,900,000 on \$4,900,000 in cash receipts. Also on May 21, 2018, Co. filed with the U.S. Bankruptcy Court a motion compelling Robinson Brog Leinwand Greene Genovese & Gluck PC to turn over and account for property of the estates and recorded information to the Debtors. The motion explains, "Beginning in or about Jan. 2012 through approximately Oct., 2017, Robinson Brog acted as the Debtors' outside general counsel. As set forth herein, Robinson Brog acted as corporate counsel on a number of transactions for the Debtors, formed a number of the debtor entities, and Robinson Brog also acted as counsel on behalf of the Debtors in several active litigations. Robinson Brog's address was used as Debtor's mailing address. The Debtors require the files in Robinson Brog's possession so that they can investigate the Debtors' affairs and conduct these chapter 11 cases. Furthermore, the limited records available to the Debtors indicate that significant amounts of Debtor funds and escrows passed through the hands of Robinson Brog. Despite repeated requests, Robinson Brog has refused to turn over files or comply with its ethical obligations to account for funds that came into its possession. To the extent Robinson Brog asserts an attorneys' retaining lien over such property, such lien does not excuse it from its obligations under section 542(e). Finally, Robinson Brog has failed to comply with provisions of the New York Rules of Professional Conduct, which require a full accounting of all funds it held and/or released for any transaction in which Robinson Brog served as escrow agent to one or more of the Debtors. Upon information and belief, Robinson Brog served as escrow agent in connection with the receipt and distribution of over \$46,000,000 related to a go-private merger transaction involving the Debtors that closed in Jan. 2017. After several attempts to contact Robinson Brog by telephone and e-mail, Robinson Brog responded late in the day on Feb. 1, 2018, stating that: (i) it had complied with its obligation to render an appropriate accounting; (ii) to the best of its knowledge, Robinson Brog does not currently hold any funds on behalf of the Debtors, but has identified one additional account that may have held funds for CHT in late 2014 and early 2015; and (iii) it is investigating the issue regarding interest on the Escrowed Funds and does not assert a right to any interest on the funds previously held in escrow. The Debtors respectfully submit that the Court should compel Robinson Brog to comply with its affirmative obligation to turn over its entire client file relating to the Debtors under section 542(a), including all ESI and correspondence generated in the course of Robinson Brog's representation of the Debtors, as well as provide a full and accurate accounting, as required under the New York Rules of Professional Responsibility, of any accounts Robinson Brog maintained on the Debtors' behalf. These materials qualify as property of the Debtors' estates under section 541 of the Bankruptcy Code, and therefore Robinson Brog has an affirmative, self-effectuating duty to turn them over to the Debtors under section 542(a). Even if these materials are determined to not be property of the Debtors' estates, they relate to the Debtors' property and financial affairs and as such must be turned over under section 542(e)." The U.S. Bankruptcy Court subsequently approved this motion. Also on May 21, 2018, Co.'s official committee of unsecured creditors filed with the U.S. Bankruptcy Court an objection to the motion approving bidding procedures relating to the sale of certain of the Debtors' assets; approving bid protections; scheduling a hearing



to consider the sale; scheduling a hearing on the proposed sale; approving the asset purchase agreement and authorizing the sale of certain of the Debtors' assets; and authorizing the sale of assets free and clear of all liens, claims, encumbrances and interests. The committee asserts, "The Committee objects to the Bidding Procedures proposed by the Debtors because they are not designed to maximize value, and instead appear to provide substantial protections to the Stalking Horse and thereby risk chilling bidding. The Committee also objects to certain terms of the APA. The Committee objects to the APA and the proposed sale order to the extent (a) they contain ambiguous terms, (b) arguably fail to preserve causes of action for the benefit of the Debtors' estates, (c) fail to disclose the assets being purchased, (d) fail to disclose the amounts for which the estates may be liable to third parties on account of alleged cure amounts, rejection damages, or claims related to employee termination, or fail to provide information necessary for other bidders to submit a competitive bid. Specifically, the Committee objects to certain terms of the sale contract as follows: The Motion does not disclose critical schedules to the APA. The Debtors should provide all schedules and other relevant documents to potential purchasers so they have time to assess such schedules and submit competing bids. This is especially critical with respect to schedules that demonstrate which assets (including contracts) are being assumed or rejected." Also on May 21, 2018, Co.'s Chief Executive Officer and TG Capital filed with the U.S. Bankruptcy Court a notice of competing bid and objection to Debtor's motion approving bidding procedures relating to the sale of certain of the Debtors' assets; approving bid protections; approving the form and manner of notice of sale by auction; establishing procedures for noticing and determining cure amounts; scheduling a hearing on the proposed sale; and approving asset purchase agreement and authorizing the sale of assets free and clear of all liens, claims, encumbrances, and interests. The objection asserts, "The Debtors' Motion contains only conclusory statements about the substance of the asset purchase agreement presented to this Court and little discussion about the sale process. Specifically, the Motion fails to disclose what contracts will be assumed or how many employees of the Debtors will be hired by the proposed purchaser. In addition, in its perfunctory recitation, the Motion fails to disclose certain troublesome facts about the sale process including: (i) that the Debtors threatened to shut down the Orion RCM Business immediately upon the commencement of the chapter 11 cases until the Objectors indicated that they would make a separate bid to purchase the Orion RCM Business; (ii) that the Debtors did not solicit uniform bids on the assets that they intended to sell and therefore, did not obtain the highest proposal to serve as the stalking horse; (iii) that the Debtors led at least the Objectors to believe that they would file chapter 11 cases for the NYNM-related assets which they never did file; and (iv) that the Debtors failed to disclose the existence of the executed letter of intent while inducing the Objectors to continue to expend resources with no apparent intention of continuing negotiations in good faith. Without providing any of that information to the Court or an affidavit describing the process in any detail, the Debtors nevertheless conclude that the offer set forth in the Motion is both the 'highest and best' proposal received. Indeed, it appears from the Motion that the Debtors misled the Objectors regarding bidding process and the selection of the stalking horse. While the Motion indicates that on Apr. 10, 2018, the Debtors received a letter of intent from the proposed purchaser for the Debtors' assets, the Motion fails to note that the Debtors never advised the Objectors that the Debtors had decided to sell only the Debtors' assets, and not the assets of the NYNM business as well. In fact, they failed to share this information even while the Objectors, their representatives, and the Debtors' representatives all participated in an in-person meeting at the offices of Debtors' counsel as late as Apr. 25, 2018. Moreover, as a result of that meeting, the Debtors' representatives induced the Objectors to prepare a further draft of an asset purchase agreement that included the NYNM assets that the Debtors apparently had no intention to sell. Had the Debtors' representatives merely indicated that they would only sell the Debtors' assets, the Objectors could have submitted this bid earlier and generated a higher and better offer for the benefit of the Debtors' estate that the Objectors have submitted now." Also on May 21, 2018, Robinson Brog Leinwand Greene Genovese & Gluck P.C. filed with the U.S. Bankruptcy Court a motion to file under seal a copy of the accounting that Robinson Brog delivered to Co. on May 17, 2018, pursuant to the Court's Order compelling Robinson Brog Leinwand Greene Genovese & Gluck PC to turnover accounting dated May 4, 2018 [Doc. No. 164]. The seal motion explains, "The accountings contain confidential, non-public financial and bank account information related to the Debtors. Accordingly, pursuant to section 107 of the Bankruptcy Code, Local Rule 9018-1, and the Order, Robinson Brog respectfully seeks entry of an order allowing it to file the accountings with the Court under seal."

**ORION HEALTHCORP INC**  
**Bankruptcy Proceedings** On May 24, 2018, the U.S. Bankruptcy Court scheduled a May 24, 2018 hearing to consider Co.'s asset sale bidding procedures.

**ORITANI FINANCIAL CORP (DE)**

**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	60,813	58,892
Operating income	55,293	71,287
Net before taxes	55,293	71,287
Income taxes	25,902	25,034
<b>Net income</b>	<b>29,391</b>	<b>46,253</b>
Earnings common share		
Primary	\$0.67	\$1.07
Fully Diluted	\$0.65	\$1.04
Common Shares:		
Full Diluted	44,984	44,380
Year-end	46,604	45,876

**OZOP SURGICAL CORP**

**New Name** On May 21, 2018, Co. changed its name from Newmarkt Corp. to OZOP Surgical Corp.

**PACCAR FINANCIAL CORP**

**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues	170,500	166,100
Cost & expenses	50,700	54,400
Operating income	26,600	20,000
Net before taxes	26,600	20,000
Income taxes	6,200	7,500
<b>Net income</b>	<b>20,400</b>	<b>12,500</b>
Earnings common share		
Common Shares:		
Year-end	145	145

**Consolidated Balance Sheet Items, as of (\$000):**

	2018	2017
Assets:		
Cash & equivalents	28,600	28,600
Current assets	28,600	28,600
Total assets	8,397,700	
Liabilities:		
Current liabilities	1,836,300	
Long-term debt	4,386,300	
Stockholders' equity	1,599,000	
Net current assets	(1,807,600)	

**PATRIOT NATIONAL INC**

**Bankruptcy Proceedings** On May 24, 2018, Co. filed with the U.S. Bankruptcy Court a motion for an order extending the exclusive periods during which the Debtors may file a Chapter 11 plan, and solicit acceptances thereof, through Aug. 28, 2018 and Oct. 29, 2018, respectively. In support of the motion, the Debtor states, "On May 4, 2018, the Court entered an order confirming the Debtors' Fourth Further Amended Joint Chapter 11 Plan of Reorganization. The Effective Date has not yet occurred, as certain conditions precedent to the occurrence of the Effective Date have not yet been met. Although the Debtors believed that these conditions precedent will ultimately be met, out of an abundance of caution, by this Motion and pursuant to section 1121(d) of the Bankruptcy Code, the Debtors seek an extension of their exclusive periods to file a chapter 11 plan (the 'Exclusive Filing Period') through and including Aug. 28, 2018, and to solicit votes to approve a chapter 11 plan (the 'Exclusive Solicitation Period') through and including Oct. 29, 2018 (together, the 'Exclusive Periods'). The Debtors' current Exclusive Periods are slated to expire on May 30, 2018 and July 30, 2018, respectively (together, the 'Current Exclusive Periods'). The requested extension will allow the Debtors to maintain the Exclusive Periods in the unlikely event that the Plan does not become effective." The Court scheduled a June 13, 2018 hearing on the extension motion with objections due by June 6, 2018.

**PCT LTD**

**New Name** On May 22, 2018, Co. changed its name from Bingham Canyon Corp. to PCT Ltd.

**PIERIS PHARMACEUTICALS INC**

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	4,152,000	1,343,000
Cost & expenses	12,288,000	9,349,000
Operating income	(8,136,000)	(8,006,000)
Other income (expense), net	(903,000)	12,000
Net before taxes	(8,714,000)	(7,994,000)
<b>Net income</b>	<b>(8,714,000)</b>	<b>(7,994,000)</b>
Earnings common share		

Primary	\$(0.17)	\$(0.19)
Fully Diluted	\$(0.17)	\$(0.19)
Common Shares:		
Full Diluted	50,046,000	43,063,790
Year-end	53,974,184	43,058,827

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	109,521,000	
Current assets	166,081,000	
Net property & equip.	4,445,000	
Total assets	173,239,000	
Liabilities:		
Current liabilities	54,763,000	
Stockholders' equity	50,693,000	
Net current assets	111,318,000	

**POCKET SHOT CO**

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	35,309	11,867
<b>Net income</b>	<b>(18,747)</b>	<b>(6,319)</b>
Earnings common share		
Common Shares:		
Year-end	6,458,657	6,458,657

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	25,818	
Inventories	60,498	
Current assets	108,180	
Net property & equip.	44,707	
Total assets	152,887	
Liabilities:		
Current liabilities	30,672	
Stockholders' equity	122,215	
Net current assets	77,508	

**POINT.360 (NEW)**

**Bankruptcy Proceedings** On May 21, 2018, Co. filed with the U.S. Bankruptcy Court a monthly operating report for Apr. 2018. For the month, the Debtors reported a net loss of \$313,155 on \$1,900,000 net sales and \$885,711 in total operating expenses. Debtors' cash at the beginning of Apr. 2018 was \$180,780 and \$111,215 at month's end, with cash disbursements of \$3,300,000 on \$3,200,000 in cash receipts.

**PREMIER BIOMEDICAL INC**

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	10,395	
Cost & expenses	80,166	74,206
Operating income	(69,771)	(74,206)
Interest expense	64,145	152,747
Other income (expense), net	700,240	(5,102,149)
<b>Net income</b>	<b>566,324</b>	<b>(5,329,102)</b>
Earnings common share		
Primary	\$	\$(0.01)
Fully Diluted	\$	\$(0.01)
Common Shares:		
Full Diluted	721,796,400	401,283,532
Year-end	747,306,550	491,852,004

**Consolidated Balance Sheet Items, as of (\$):**

	2018	2017
Assets:		
Cash & equivalents	79,221	
Inventories	79,410	
Current assets	191,958	
Net property & equip.	6,916	
Total assets	198,874	
Liabilities:		
Current liabilities	2,126,006	
Stockholders' equity	(1,927,132)	
Net current assets	(1,934,048)	

**PREMIER EXHIBITIONS INC**

**Bankruptcy Proceedings** On May 22, 2018, Co.'s official committee of unsecured creditors filed with the U.S. Bankruptcy Court an objection to (a) an emergency motion of the official committee of equity security holders for derivative standing to prosecute litigation on behalf of the Debtors' estates and (b) an emergency application to employ Robert Charbonneau and Agentis PLLC as special counsel to the equity committee. The committee asserts, "The marketing process for the sale of the Debtors' assets pursuant to the plan support agreement has been underway for over a year. As of May 22, 2018 that process has failed to yield a complete sale transaction that would pay creditors in full,

even though this Court has long since entered judgment in the Debtors' favor in the adversary proceeding against the Republic of France. The Equity Committee now seeks authority to prosecute a long-shot litigation that it wants creditors to fund, after wasting well over \$1,000,000 in estate funds taking discovery and investigating potential claims. Until such time as creditors are paid in full, or sufficient funds are secured by the Debtors' estates to pay creditors in full, the Equity Committee cannot be allowed to waste estate resources on speculative litigation that has little chance of yielding significant recoveries. The Equity Committee advised the Creditors' Committee that it was in the process of securing contingency counsel, and was still exploring securing litigation financing to fund associated costs. That is unacceptable. The cost of a single damages expert could easily run well into the seven figures in complex litigation, putting aside additional costs associated with litigation such as transcription and travel costs. If derivative standing is granted and the Employment Application is approved, creditors will be required to pay for those expenses even if they significantly erode creditor recoveries and the litigation proves a bust."

#### PURPLE INNOVATION INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total revenues	60,980,000	60,980,000
Cost & expenses	63,898,000	314,000
Operating income	(2,918,000)	(314,000)
Interest income		179,000
Interest expense	702,000	18,000
Other income (expense), net	19,000	
Net before taxes	(153,000)	
Income taxes		50,000
Net income	(3,601,000)	(203,000)
Balance for common		(203,000)
Earnings common share		
Primary	\$(0.17)	\$(0.04)
Fully Diluted	\$(0.17)	\$(0.04)
Common Shares:		
Full Diluted	8,389,000	4,986,000
Year-end	53,754,000	4,997,706

#### Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	26,843,000	
Inventories	26,579,000	
Current assets	61,799,000	
Net property & equip.	16,127,000	
Total assets	79,250,000	
Liabilities:		
Current liabilities	43,517,000	
Long-term debt	19,081,000	
Stockholders' equity	1,833,000	
Net current assets	18,282,000	

#### QUALSTAR CORP

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	2,345,000	2,381,000
Operating income	590,000	58,000
Net before taxes	590,000	58,000
Net income	590,000	58,000
Earnings common share		
Primary	\$0.29	\$0.03
Fully Diluted	\$0.28	\$0.03
Common Shares:		
Full Diluted	2,101,000	2,042,000
Year-end	2,048,118	2,042,000

#### Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	5,231,000	
Inventories	1,611,000	
Current assets	9,094,000	
Net property & equip.	141,000	
Total assets	9,302,000	
Liabilities:		
Current liabilities	2,643,000	
Stockholders' equity	6,520,000	
Net current assets	6,451,000	

#### QUANTRX BIOMEDICAL CORP

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	46,303	35,614
Operating income	(46,603)	(36,508)
Net before taxes	(105,000)	(92,671)
Net income	(105,000)	(92,671)

#### Earnings common share

Common Shares:

Full Diluted	78,696,461	78,696,461
Year-end	78,696,461	78,696,461

#### Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	803,114	
Current assets	821,888	
Total assets	1,321,888	
Liabilities:		
Current liabilities	2,176,439	
Stockholders' equity	(854,551)	
Net current assets	(1,354,551)	

#### QUANTUM FUEL SYSTEMS TECHNOLOGIES WORLD-WIDE INC.

Bankruptcy Proceedings On May 21, 2018, Co. filed with the U.S. Bankruptcy Court a monthly operating report for Apr. 2018. For the period, Co. reported net loss of \$21,568 on zero net sales/revenue. Co. posted \$11,568 in total non-operating expenses.

#### RAIN FOREST INTERNATIONAL INC

New Name On May 22, 2018, Co. changed its name from GVCL Ventures Inc. to Rain Forest International Inc.

#### REALBIZ MEDIA GROUP INC

Earnings, 3 mos. to Jan 31(Consol. - \$):

	2018	2017
Total revenues	1,066,141	101,633
Cost & expenses	1,334,306	997,667
Operating income	(268,165)	(896,033)
Interest expense	49,358	83,703
Other income (expense), net	(189,483)	(23,716)
Net income	(507,006)	(1,003,452)
Earnings common share		
Common Shares:		
Full Diluted	274,118,608	183,046,600
Year-end	359,447,396	241,654,943

#### Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	657,511	
Inventories	185,689	
Current assets	1,789,536	
Total assets	1,789,536	
Liabilities:		
Current liabilities	2,564,298	
Stockholders' equity	(774,762)	
Net current assets	(774,762)	

#### RED VIOLET INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total revenues	3,325	1,572
Cost & expenses	4,958	4,249
Deprec., depl. & amort.	451	216
Operating income	(2,084)	(2,893)
Net before taxes	(2,084)	(2,893)
Net income	(2,084)	(2,893)
Earnings common share		
Primary	\$(0.20)	\$(0.28)
Fully Diluted	\$(0.20)	\$(0.28)
Common Shares:		
Full Diluted	10,267	10,267
Year-end	10,267	

#### Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	19,793	
Current assets	22,621	
Net property & equip.	974	
Total assets	46,535	
Liabilities:		
Current liabilities	6,273	
Stockholders' equity	40,262	
Net current assets	16,348	

#### RELIANT SERVICE INC

Earnings, 9 mos. to Apr 30(Consol. - \$):

	2018	2017
Cost & expenses	95,807	147,682
Operating income	(2,692)	(39,205)
Net before taxes	(2,692)	(39,205)
Income taxes	(404)	(5,881)
Net income	(2,288)	(33,324)
Earnings common share		

Primary	\$(0.00)	\$(0.01)
Fully Diluted	\$(0.00)	\$(0.01)
Common Shares:		
Full Diluted	5,015,000	5,015,000
Year-end	5,015,000	5,015,000

#### REMARK HOLDINGS INC

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total revenues	16,724,000	15,299,000
Cost & expenses	35,212,000	17,818,000
Operating income	(21,206,000)	(5,380,000)
Other income (expense), net	8,621,000	6,588,000
Gains or losses	(31,000)	(31,000)
Net before taxes	(14,022,000)	159,000
Income taxes	31,000	184,000
Net income	(14,053,000)	(25,000)

#### Earnings common share

Primary	\$(0.43)	\$(0.43)
Fully Diluted	\$(0.43)	\$(0.43)

Common Shares:

Full Diluted	32,395,000	22,468,000
Year-end	32,843,399	22,614,312

#### Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	21,851,000	
Inventories	330,000	
Current assets	42,026,000	
Net property & equip.	13,423,000	
Total assets	102,806,000	
Liabilities:		
Current liabilities	71,423,000	
Long-term debt	26,908,000	
Stockholders' equity	(21,210,000)	
Net current assets	(29,397,000)	

#### RESORT SAVERS INC

Acquisition Completed On May 16, 2018, Co.'s wholly-owned subsidiary, Huaxin Changrong (Shenzhen) Technology Service Co., Ltd. ("Huaxin"), acquired the remaining 49% interest in Beijing Yandong Tieshan Oil Products Co., Ltd. ("Tieshan Oil") from Mr. Yang Baojijin ("Mr. Yang") in exchange of 16,000,000 shares of Co.'s common stock, par value \$0.0001 per share. Also on May 16, 2018, Co. acquired 100% of the outstanding equity interests of Admall Sdn. Bhd. ("Admall"), a company engaged in the business of digital advertising and education, from Mr. Boon Jin "Patrick" Tan in exchange Co. issued 400,000,000 shares of Common Stock to Mr. Tan, which at the time of closing represented approximately 81.47% of Co.'s outstanding Common Stock. As the result, Admall became a wholly-owned subsidiary of Co.

#### REX ENERGY CORP

Bankruptcy Proceedings On May 18, 2018, Co. and certain of its wholly-owned subsidiaries (together with Co., the "Debtors") filed voluntary petitions (the "Bankruptcy Petitions") for reorganization under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Western District of Pennsylvania (the "Bankruptcy Court"). The Debtors have filed a motion with the Bankruptcy Court seeking to jointly administer all of the Debtors' chapter 11 cases (the "Chapter 11 Cases") under the caption In re R.E. Gas Development, LLC, Case No. 18-22032. The Debtors will continue to operate their businesses as "debtors-in-possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. Co. has filed a series of first day motions with the Court that will allow it to continue to conduct business without interruption. These motions are designed primarily to minimize the effect of bankruptcy on Co.'s operations, customers and employees. Co. expected to continue operations in the normal course during the pendency of the Chapter 11 Cases, and anticipates making royalty payments and payments to working interest owners when due, subject to Bankruptcy Court approval. Employees should expect no change in their daily responsibilities and to be paid in the ordinary course of business.

#### REX ENERGY CORP

Bankruptcy Proceedings On May 23, 2018, the U.S. Bankruptcy Court approved, on an interim basis, Co.'s motion for entry of interim and final orders (i) authorizing the Debtors to obtain superpriority D.I.P. financing, pursuant to the terms set forth in the D.I.P. credit agreement; (ii) authorizing the Debtors to use cash collateral; (iii) granting priming liens and superpriority administrative claims; (iv) approving the form of adequate protection to be provided by the Debtors; and (v) scheduling a final

hearing to consider entry of the final order. As previously reported, "The proposed DIP Facility consists of a senior term loan credit facility in the aggregate principal amount of \$411,315,322 among: (a) Co. ("Co." or the "DIP Borrower"), as borrower; (b) the DIP Lenders; (c) Macquarie Bank Limited, as Issuing Bank; and (d) Angelo, Gordon Energy Servicer, LLC (Angelo, Gordon), as DIP Agent. In accordance with the RSA, the DIP Facility will consist of \$100,000,000 of new money and \$311,315,322 that will be used to convert the existing obligations under the Prepetition First Lien Credit Agreement into loans under the DIP Facility. The obligations existing under the Prepetition First Lien Credit Agreement that will be converted into the DIP Facility include certain make-whole payments that are due and owing under the Prepetition First Lien Credit Agreement. As part of the settlement embodied in the RSA, those make-whole obligations will be limited to \$50,000,000, subject to certain upward and downward adjustments of the Interim Order and the RSA." As of the date of the court order, the Debtors are authorized to borrow up to \$40,000,000 under the D.I.P. Facility on an interim basis. The Court scheduled a June 21, 2018 final hearing on the financing motion with objections due by June 14, 2018.

#### REX ENERGY CORP

**Bankruptcy Proceedings** On May 21, 2018, Co. filed with the U.S. Bankruptcy Court a motion for entry of interim and final orders (i) authorizing the Debtors to obtain superpriority D.I.P. financing, pursuant to the terms set forth in the D.I.P. credit agreement; (ii) authorizing the Debtors to use cash collateral; (iii) granting priming liens and superpriority administrative claims; (iv) approving the form of adequate protection to be provided by the Debtors; (v) modifying the automatic stay to the extent necessary to effectuate the terms of the DIP Orders; and (vi) scheduling a final hearing to consider entry of the final order. The motion explains, "The proposed DIP Facility consists of a senior term loan credit facility in the aggregate principal amount of \$411,315,322 among: (a) Co. ("Co." or the "DIP Borrower"), as borrower; (b) the DIP Lenders; (c) Macquarie Bank Limited, as Issuing Bank; and (d) Angelo, Gordon Energy Servicer, LLC ("Angelo, Gordon"), as DIP Agent. In accordance with the RSA, the DIP Facility will consist of \$100,000,000 of new money and \$311,315,322 that will be used to convert the existing obligations under the Prepetition First Lien Credit Agreement into loans under the DIP Facility. The obligations existing under the Prepetition First Lien Credit Agreement that will be converted into the DIP Facility include certain make-whole payments that are due and owing under the Prepetition First Lien Credit Agreement. As part of the settlement embodied in the RSA, those make-whole obligations will be limited to \$50,000,000, subject to certain upward and downward adjustments of the Interim Order and the RSA."

#### RICEBRAN TECHNOLOGIES

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	3,552,000	3,615,000
Cost & expenses	5,451,000	4,694,000
Operating income	(1,899,000)	(1,079,000)
Other income (expense), net	(13,000)	(676,000)
Net before taxes	(1,913,000)	(2,810,000)
Income taxes		(397,000)
Income contin. oper.	(1,913,000)	(2,413,000)
<b>Net income</b>	(1,913,000)	(2,601,000)
Balance for common	(1,913,000)	(3,060,000)
Earnings common share		
Primary	\$(0.11)	\$(0.32)
Fully Diluted	\$(0.11)	\$(0.32)
Common Shares:		
Full Diluted	17,083,442	9,657,543
Year-end	19,953,107	

#### Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	5,130,000
Inventories	765,000
Current assets	8,661,000
Net property & equip.	7,985,000
Total assets	16,694,000
Liabilities:	
Current liabilities	1,788,000
Long-term debt	11,000
Stockholders' equity	14,895,000
Net current assets	6,873,000

#### RICEBRAN TECHNOLOGIES

**New Accountant** On May 17, 2018, Co. dismissed Marcum LLP and engaged RSM USA LLP as its new independent public accounting firm.

#### RLJ ENTERTAINMENT INC

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	18,582,000	13,887,000
Cost & expenses	19,358,000	15,927,000
Deprec., depl. & amort.	885,000	873,000
Operating income	(1,661,000)	(2,913,000)
Interest expense	2,291,000	1,886,000
Other income (expense), net	(2,360,000)	(1,162,000)
Net before taxes	(6,312,000)	(5,961,000)
Income taxes	213,000	161,000
<b>Net income</b>	(6,525,000)	(6,122,000)
Balance for common	(6,718,000)	(6,499,000)
Earnings common share		
Primary	\$(0.46)	\$(1.26)
Fully Diluted	\$(0.46)	\$(1.26)
Common Shares:		
Full Diluted	14,467,000	5,164,000
Year-end	14,564,678	5,472,023

#### Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	4,230,000
Inventories	4,307,000
Current assets	102,329,000
Net property & equip.	1,106,000
Total assets	147,762,000
Liabilities:	
Current liabilities	63,522,000
Long-term debt	53,702,000
Stockholders' equity	10,843,000
Net current assets	38,807,000

#### SABAN CAPITAL ACQUISITION CORP

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	721,956	210,968
Cost & expenses	440,524	222,512
Interest expense	510	
<b>Net income</b>	280,922	(11,544)
Earnings common share		
Primary	\$0.01	\$
Fully Diluted	\$0.01	\$
Common Shares:		
Full Diluted	25,000,000	25,000,000
Year-end	7,402,839	31,250,000

#### Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	579,701
Current assets	626,050
Total assets	253,069,802
Liabilities:	
Current liabilities	913,393
Stockholders' equity	5,000,001
Net current assets	(287,343)

#### SANSAL WELLNESS HOLDINGS INC

**Earnings, 3 mos. to (Consol. - \$):**

	03/31/18	04/30/17
Net Sales	331,416	
Cost & expenses	698,948	13,598
Operating income	(367,532)	
Other income (expense), net	23,927	
Net before taxes	(353,295)	
<b>Net income</b>	(353,295)	(13,598)
Earnings common share		
Primary	\$(0.01)	\$
Fully Diluted	\$(0.01)	\$
Common Shares:		
Full Diluted	60,060,978	56,700,000
Year-end	60,169,000	56,700,000

#### Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Inventories	1,485,234
Current assets	1,601,490
Net property & equip.	3,545,922
Total assets	5,170,412
Liabilities:	
Current liabilities	2,162,405
Long-term debt	99,901
Stockholders' equity	2,908,106
Net current assets	(560,915)

#### SCOOBEEZ GLOBAL INC

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	8,252,551	8,136,058
Cost & expenses	8,481,516	11,302,081
Operating income	(265,096)	(3,200,385)
Interest expense	495,330	1,836,266
Other income (expense), net	(1,796)	(494,796)
Net before taxes	(762,221)	(5,531,447)
Income taxes		(148,365)
<b>Net income</b>	(762,221)	(5,383,082)
Earnings common share		
Primary	\$(0.03)	\$(0.03)
Fully Diluted	\$(0.03)	\$(0.03)
Common Shares:		
Full Diluted	167,986,270	163,373,273
Year-end	167,986,270	

#### Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	16,152
Current assets	6,070,481
Net property & equip.	127,251
Total assets	7,803,626
Liabilities:	
Current liabilities	21,693,940
Long-term debt	1,323,500
Stockholders' equity	(13,940,490)
Net current assets	(15,623,459)

#### SECTOR 5 INC

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	490	89,484
Cost & expenses	193,631	163,828
Operating income	(193,141)	(74,344)
Interest expense	1,050	1,296
Net before taxes	(194,191)	(75,640)
<b>Net income</b>	(194,191)	(75,640)
Earnings common share		
Primary	\$(0.01)	\$
Fully Diluted	\$(0.01)	\$
Common Shares:		
Full Diluted	18,061,644	18,000,000
Year-end	18,500,000	18,000,000

#### Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	35
Inventories	7,021
Current assets	7,056
Total assets	7,056
Liabilities:	
Current liabilities	485,624
Stockholders' equity	(478,568)
Net current assets	(478,568)

#### SELLAS LIFE SCIENCES GROUP INC

**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	5,684,000	5,088,000
Operating income	(5,684,000)	(5,088,000)
Interest expense	96,000	
Other income (expense), net	(2,215,000)	3,779,000
Income contin. oper.		(2,282,000)
Income discont. oper.		(9,436,000)
<b>Net income</b>	(7,995,000)	(11,718,000)
Balance for common	(9,963,000)	
Earnings common share		
Primary	\$(1.67)	\$(13.50)
Fully Diluted	\$(1.67)	\$(13.50)
Common Shares:		
Full Diluted	5,952,193	880,212
Year-end	6,154,377	1,238,277

#### Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	3,474,000
Current assets	13,072,000
Total assets	33,485,000
Liabilities:	
Current liabilities	25,747,000
Long-term debt	1,150,000
Stockholders' equity	(1,318,000)
Net current assets	(12,675,000)

#### SEMLER SCIENTIFIC INC

**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total revenues	4,463	2,055
Cost & expenses	3,650	2,805
Operating income	813	(750)
Other income (expense), net	(1)	5
<b>Net income</b>	<b>706</b>	<b>(871)</b>
Earnings common share		
Primary	\$0.12	\$(0.17)
Fully Diluted	\$0.10	\$(0.17)
Common Shares:		
Full Diluted	7,280	5,231
Year-end	5,945	5,314

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	2017
Cash & equivalents	419	419
Current assets	3,000	3,000
Net property & equip.	203	203
Total assets	4,257	4,257
Liabilities:		
Current liabilities	5,752	5,752
Long-term debt	16	16
Stockholders' equity	(1,524)	(1,524)
Net current assets	(2,752)	(2,752)

**SITO MOBILE LTD****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	11,144,652	6,552,748
Cost & expenses	16,907,510	9,202,426
Deprec., depl. & amort.	184,757	161,764
Operating income	(5,947,615)	(2,811,442)
Other income (expense), net	86,079	92,213
Gains or losses	641,216	641,216
Net before taxes	(5,216,346)	(3,110,843)
Income taxes	31,385	31,385
Income contin. oper.	(5,247,731)	(3,110,843)
Income discount. oper.	51,376	51,376
<b>Net income</b>	<b>(5,247,731)</b>	<b>(3,059,467)</b>

Earnings common share		
Primary	\$(0.22)	\$(0.15)
Fully Diluted	\$(0.22)	\$(0.15)
Common Shares:		
Full Diluted	23,724,307	20,681,047
Year-end	25,115,570	25,115,570

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	2017
Cash & equivalents	11,937,009	11,937,009
Current assets	21,421,238	21,421,238
Net property & equip.	451,970	451,970
Total assets	31,523,831	31,523,831
Liabilities:		
Current liabilities	11,557,938	11,557,938
Long-term debt	10,328	10,328
Stockholders' equity	19,955,565	19,955,565
Net current assets	9,863,300	9,863,300

**SKY RESORT INTERNATIONAL LTD****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	26,581	6,599
Operating income	(26,581)	(6,599)
<b>Net income</b>	<b>(26,581)</b>	<b>(6,599)</b>
Earnings common share		
Primary	\$(0.13)	\$(0.03)
Fully Diluted	\$(0.13)	\$(0.03)
Common Shares:		
Full Diluted	201,538	201,431
Year-end	201,538	201,431

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	2017
Current assets	2,200	2,200
Total assets	2,200	2,200
Liabilities:		
Current liabilities	260,260	260,260
Stockholders' equity	(258,060)	(258,060)
Net current assets	(258,060)	(258,060)

**SMSA CRANE ACQUISITION CORP.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	6,881	818
Operating income	(6,881)	(818)
<b>Net income</b>	<b>(6,881)</b>	<b>(818)</b>

Earnings common share		
Common Shares:		
Full Diluted	10,047,495	11,663,448
Year-end	10,047,495	11,663,448

**SOLAR QUARTZ TECHNOLOGY CORP****Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	1,689,040	8,734
Operating income	(1,689,040)	(8,734)
Interest income	(1)	(1)
Net before taxes	(1,698,597)	(18,290)
<b>Net income</b>	<b>(1,698,597)</b>	<b>(18,290)</b>
Earnings common share		
Primary	\$ (0.02)	\$(0.02)
Fully Diluted	\$ (0.02)	\$(0.02)
Common Shares:		
Full Diluted	224,676,229	1,002,134
Year-end	234,451,148	1,002,134

**SOLENO THERAPEUTICS INC****Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	3,475	1,373
Operating income	(3,475)	(1,373)
Other income (expense), net	215	(71)
Income contin. oper.	(3,241)	(2,045)
Income discount. oper.	(514)	(842)
<b>Net income</b>	<b>(3,755)</b>	<b>(2,887)</b>
Earnings common share		
Primary	\$(0.19)	\$(0.57)
Fully Diluted	\$(0.19)	\$(0.57)
Common Shares:		
Full Diluted	19,530	5,091
Year-end	19,768	19,768

**Consolidated Balance Sheet Items, as of (\$000):**

Assets:	2018	2017
Cash & equivalents	14,866	14,866
Current assets	15,808	15,808
Net property & equip.	17	17
Total assets	36,331	36,331
Liabilities:		
Current liabilities	1,942	1,942
Stockholders' equity	23,019	23,019
Net current assets	13,866	13,866

**SPECTRUM GLOBAL SOLUTIONS INC (NV)****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	4,327,764	4,327,764
Cost & expenses	5,023,422	134,270
Deprec., depl. & amort.	47,833	5,603
Operating income	(743,491)	(139,873)
Other income (expense), net	1,413,688	(736,858)
Gains or losses	(2,067)	(2,067)
<b>Net income</b>	<b>(163,215)</b>	<b>(1,042,574)</b>
Earnings common share		
Primary	\$ (0.01)	\$(0.01)
Fully Diluted	\$ (0.01)	\$(0.01)
Common Shares:		
Full Diluted	445,161,856	117,272,240
Year-end	460,682,237	460,682,237

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	2017
Cash & equivalents	285,339	285,339
Current assets	6,751,851	6,751,851
Net property & equip.	65,652	65,652
Total assets	12,926,323	12,926,323
Liabilities:		
Current liabilities	18,618,838	18,618,838
Stockholders' equity	(5,415,838)	(5,415,838)
Net current assets	(11,866,987)	(11,866,987)

**SUNESIS PHARMACEUTICALS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	237,000	669,000
Cost & expenses	7,328,000	10,104,000
Operating income	(7,091,000)	(9,435,000)
Interest expense	281,000	484,000
Other income (expense), net	99,000	85,000
<b>Net income</b>	<b>(7,273,000)</b>	<b>(9,834,000)</b>

Earnings common share		
Primary	\$(0.21)	\$(0.47)
Fully Diluted	\$(0.21)	\$(0.47)
Common Shares:		
Full Diluted	34,345,000	21,029,000
Year-end	34,371,173	21,460,543

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	2017
Cash & equivalents	21,365,000	21,365,000
Current assets	26,878,000	26,878,000
Net property & equip.	18,000	18,000
Total assets	26,992,000	26,992,000
Liabilities:		
Current liabilities	11,627,000	11,627,000
Stockholders' equity	15,365,000	15,365,000
Net current assets	15,251,000	15,251,000

**SUNSHINE BIOPHARMA INC.****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	91,168	91,168
Cost & expenses	251,125	108,472
Operating income	(166,697)	(108,990)
Other income (expense), net	(38,340)	(76,929)
Foreign currency	14,868	(639)
<b>Net income</b>	<b>(265,636)</b>	<b>(195,702)</b>

Earnings common share		
Common Shares:		
Year-end	949,019,532	817,927,983

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018	2017
Cash & equivalents	104,763	104,763
Current assets	202,489	202,489
Net property & equip.	118,444	118,444
Total assets	1,002,335	1,002,335
Liabilities:		
Current liabilities	1,180,999	1,180,999
Long-term debt	322,021	322,021
Stockholders' equity	(500,685)	(500,685)
Net current assets	(978,510)	(978,510)

**SUREQUEST SYSTEMS INC. (DE)**

**Sale Completed** On May 18, 2018, Co. was acquired by MealSuite Inc., a provider of software solutions, for \$0.0245 in cash for each Common share held.

**SYNTHESIS ENERGY SYSTEMS INC****Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	1,152,000	27,000
Cost & expenses	5,708,000	8,244,000
Operating income	(4,583,000)	(8,274,000)
Other income (expense), net	1,770,000	(40,000)
Foreign currency	219,000	(124,000)
Income contin. oper.	(3,115,000)	(8,427,000)
Income discount. oper.	1,929,000	1,929,000
<b>Net income</b>	<b>(3,115,000)</b>	<b>(6,498,000)</b>

Earnings common share		
Primary	\$(0.24)	\$(0.56)
Fully Diluted	\$(0.24)	\$(0.56)
Common Shares:		
Full Diluted	10,953,000	10,884,000
Year-end	10,982,000	10,913,875

**TELEHEALTHCARE INC****Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	509	509
Cost & expenses	488,421	2,821,366
Operating income	(488,421)	(2,820,857)
Interest expense	17,219	1,200
Net before taxes	(505,640)	(2,822,057)
<b>Net income</b>	<b>(505,640)</b>	<b>(2,822,057)</b>

Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	89,604,830	149,047,033
Year-end	89,970,139	88,373,000



Stockholders' equity ..... 535,080,000  
 Net current assets ..... 733,392,000

**URBAN ONE INC****Earnings, 3 mos. to Mar 31**(Consol. - \$000):

	2018	2017
Total revenues .....	99,621	101,289
Cost & expenses .....	84,018	76,524
Deprec., depl. & amort. ....	8,288	8,312
Operating income .....	7,315	16,453
Other income (expense), net .....	2,140	1,321
Net before taxes .....	(9,682)	(2,469)
Income taxes .....	12,840	(112)
<b>Net income</b> .....	<b>(22,522)</b>	<b>(2,352)</b>
Balance for common .....	(22,555)	(2,313)
Earnings common share		
Primary .....	\$(0.48)	\$(0.05)
Fully Diluted .....	\$(0.48)	\$(0.05)
Common Shares:		
Full Diluted .....	46,757	47,965
Year-end .....	48,544	48,326

**Consolidated Balance Sheet Items, as of** (\$000):

	2018	2017
Assets:		
Cash & equivalents .....	42,958	
Current assets .....	190,901	
Net property & equip. ....	24,347	
Total assets .....	1,305,558	
Liabilities:		
Current liabilities .....	91,207	
Long-term debt .....	956,021	
Stockholders' equity .....	17,323	
Net current assets .....	99,694	

**US LITHIUM CORP****Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2018	2017
Cost & expenses .....	16,074	24,727
Operating income .....	(16,074)	(24,727)
<b>Net income</b> .....	<b>(50,099)</b>	<b>(62,012)</b>
Earnings common share		
Common Shares:		
Full Diluted .....	102,630,366	93,912,559
Year-end .....	105,042,923	98,712,559

**Consolidated Balance Sheet Items, as of** (\$):

	2018	2017
Assets:		
Cash & equivalents .....	60,251	
Current assets .....	60,251	
Net property & equip. ....	316,045	
Total assets .....	376,296	
Liabilities:		
Current liabilities .....	414,597	
Stockholders' equity .....	(38,301)	
Net current assets .....	(354,346)	

**VAPOR GROUP INC****Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2018	2017
Total revenues .....	27,137	65,615
Cost & expenses .....	500,097	614,681
Operating income .....	(473,383)	(550,227)
Other income (expense), net .....	(688,895)	52,967
<b>Net income</b> .....	<b>(1,162,278)</b>	<b>(497,260)</b>
Earnings common share		
Primary .....	\$	\$(0.00)
Fully Diluted .....		
Common Shares:		
Year-end .....	6,255,356,184,222,963,021	

**Consolidated Balance Sheet Items, as of** (\$):

	2018	2017
Assets:		
Cash & equivalents .....	23,527	
Inventories .....	649,038	
Current assets .....	1,517,491	
Net property & equip. ....	4,755	
Total assets .....	1,844,768	
Liabilities:		
Current liabilities .....	5,129,980	
Stockholders' equity .....	(3,480,118)	
Net current assets .....	(3,612,489)	

**VASCO DATA SECURITY INTERNATIONAL INC****Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2018	2017
Total revenues .....	45,432,000	41,965,000
Cost & expenses .....	41,583,000	39,464,000

Operating income .....	1,648,000	302,000
Other income (expense), net .....	380,000	214,000
Net before taxes .....	2,421,000	806,000
Income taxes .....	629,000	233,000
<b>Net income</b> .....	<b>1,792,000</b>	<b>573,000</b>
Earnings common share		
Primary .....	\$0.04	\$0.01
Fully Diluted .....	\$0.04	\$0.01
Common Shares:		
Full Diluted .....	40,059,000	39,770,000
Year-end .....	40,312,000	40,198,000

**Consolidated Balance Sheet Items, as of** (\$):

	2018	2017
Assets:		
Cash & equivalents .....	126,484,000	
Inventories .....	11,504,000	
Current assets .....	228,285,000	
Net property & equip. ....	6,300,000	
Total assets .....	346,868,000	
Liabilities:		
Current liabilities .....	57,352,000	
Stockholders' equity .....	254,226,000	
Net current assets .....	170,933,000	

**VECTIQ ACQUISITION CORP****Annual Report****Consolidated Income Statement, Years Ended Mar. 31** (\$):

	2018
General & administrative expenses .....	462
<b>Net income (loss)</b> .....	<b>(462)</b>
Weighted average shares outstanding - basic .....	5,000,000
Weighted average shares outstanding - diluted .....	5,000,000
Year end shares outstanding .....	5,750,000
Net earnings (loss) per share - basic .....	\$0.00
Net earnings (loss) per share - diluted .....	\$0.00
Total number of employees .....	4

For the period from January 23, 2018 (inception) through March 31, 2018

**Consolidated Balance Sheet, Years Ended Mar. 31** (\$):

	2018
Cash .....	25,000
Total current assets .....	25,000
Deferred offering costs associated with initial public offering .....	179,000
Total non-current assets .....	179,000
Total assets .....	204,000
Accounts payable .....	89,462
Notes payable-related parties .....	90,000
Total current liabilities .....	179,462
Common stock .....	575
Additional paid-in capital .....	24,425
Retained earnings (accumulated deficit) .....	(462)
Total stockholders' equity .....	24,538

**Recent Dividends:**

**1. VectoIQ Acquisition Corp common.**  
 No dividends paid.

**Annual Dividends:**

**1. VectoIQ Acquisition Corp common.**  
 No dividends paid.

**VEGA BIOFUELS INC****Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2017	2016
Total revenues .....	82,387	45,754
Cost & expenses .....	182,000	212,269
Operating income .....	(99,613)	(166,515)
<b>Net income</b> .....	<b>(99,613)</b>	<b>(166,515)</b>
Earnings common share		
Primary .....	\$(0.08)	\$(0.65)
Fully Diluted .....	\$(0.08)	\$(0.65)
Common Shares:		
Full Diluted .....	1,225,079	257,030
Year-end .....	463,618,612	105,516

**VIEW SYSTEMS, INC.****Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2018	2017
Total revenues .....	73,628	8,764
Cost & expenses .....	141,471	30,311

Operating income .....	(67,843)	(21,547)
Interest expense .....	22,997	9,156
Other income (expense), net .....	(94,042)	
<b>Net income</b> .....	<b>(184,882)</b>	<b>(30,703)</b>

## Earnings common share

Common Shares:		
Full Diluted .....	326,705,526	326,705,526
Year-end .....	326,705,526	326,705,526

**Consolidated Balance Sheet Items, as of** (\$):

	2018	2017
Assets:		
Cash & equivalents .....	9,226	
Current assets .....	40,421	
Total assets .....	41,618	
Liabilities:		
Current liabilities .....	2,196,219	
Stockholders' equity .....	(2,154,601)	
Net current assets .....	(2,155,798)	

**VIRTUAL CRYPTO TECHNOLOGIES INC****Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2018	2017
Cost & expenses .....	1,428,294	68,650
Operating income .....	(1,428,294)	(68,650)
Other income (expense), net .....	(19,374,082)	(198,450)
Income contin. oper. ....	(20,802,376)	(267,100)
Income discont. oper. ....		(290,786)
<b>Net income</b> .....	<b>(20,802,376)</b>	<b>(557,887)</b>
Earnings common share		
Primary .....	\$(0.48)	\$(0.03)
Fully Diluted .....	\$(0.48)	\$(0.03)
Common Shares:		
Full Diluted .....	41,048,456	20,443,063
Year-end .....	22,543,008	

**Consolidated Balance Sheet Items, as of** (\$):

	2018	2017
Assets:		
Cash & equivalents .....	1,449,795	
Current assets .....	1,478,498	
Total assets .....	1,478,498	
Liabilities:		
Current liabilities .....	921,270	
Stockholders' equity .....	557,128	
Net current assets .....	557,228	

**VIVA ENTERTAINMENT GROUP INC****Earnings, 3 mos. to Jan 31**(Consol. - \$):

	2018	2017
Cost & expenses .....	1,200,821	236,548
Operating income .....	(1,187,660)	(236,548)
Other income (expense), net .....	(229,613)	(252,265)
<b>Net income</b> .....	<b>(1,580,592)</b>	<b>(978,819)</b>
Earnings common share		
Primary .....	\$	\$(0.01)
Fully Diluted .....	\$	\$(0.01)
Common Shares:		
Full Diluted .....	4,860,360,832	102,931,195
Year-end .....	5,066,026,602	247,815,148

**Consolidated Balance Sheet Items, as of** (\$):

	2018	2017
Assets:		
Cash & equivalents .....	58,035	
Current assets .....	58,035	
Total assets .....	110,821	
Liabilities:		
Current liabilities .....	2,976,314	
Stockholders' equity .....	(2,865,493)	
Net current assets .....	(2,918,279)	

**VIVEVE MEDICAL INC****Earnings, 3 mos. to Mar 31**(Consol. - \$):

	2018	2017
Total revenues .....	3,699,000	3,041,000
Cost & expenses .....	15,039,000	9,457,000
Operating income .....	(11,340,000)	(6,416,000)
Interest expense .....	1,070,000	263,000
Other income (expense), net .....	(10,000)	(16,000)
<b>Net income</b> .....	<b>(12,420,000)</b>	<b>(6,695,000)</b>
Earnings common share		
Primary .....	\$(0.49)	\$(0.57)
Fully Diluted .....	\$(0.49)	\$(0.57)
Common Shares:		
Full Diluted .....	25,846,724	11,663,765
Year-end .....	31,254,716	19,346,856

**Consolidated Balance Sheet Items, as of** (\$):

Assets:	2018
Cash & equivalents	38,378,000
Inventories	3,828,000
Current assets	52,507,000
Net property & equip.	1,674,000
Total assets	56,636,000
Liabilities:	
Current liabilities	8,122,000
Long-term debt	29,334,000
Stockholders' equity	18,962,000
Net current assets	44,385,000

**VIVOS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	4,054	4,054
Cost & expenses	286,694	368,029
Deprec., depl. & amort.		740
Operating income	(286,694)	(364,715)
Interest expense	632,074	527,951
Other income (expense), net	17,583	473,100
Gains or losses		2,800
Net before taxes	(901,185)	(416,766)
<b>Net income</b>	<b>(901,185)</b>	<b>(416,766)</b>
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	66,514,118	38,021,103
Year-end	72,067,213	41,967,897

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	16
Current assets	16
Total assets	685
Liabilities:	
Current liabilities	5,088,031
Stockholders' equity	(5,087,346)
Net current assets	(5,088,015)

**VVUE INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	15,483	
Cost & expenses	212,457	323,828
Operating income	(196,974)	(323,828)
Other income (expense), net	3,594	(28,819)
<b>Net income</b>	<b>(193,380)</b>	<b>(352,647)</b>
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	74,335,070	69,021,816
Year-end	74,335,070	65,370,930

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	15,916
Current assets	22,583
Total assets	314,249
Liabilities:	
Current liabilities	2,916,899
Stockholders' equity	(2,902,650)
Net current assets	(2,894,316)

**VUZIX CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	1,543,895	1,210,663
Cost & expenses	6,621,883	4,997,041
Deprec., depl. & amort.	273,622	239,830
Operating income	(5,351,610)	(4,026,208)
Other income (expense), net	(28,542)	7,350
Gains or losses	28,133	22,560
Foreign currency	(4,418)	1,097
Net before taxes	(5,365,650)	(4,181,812)
<b>Net income</b>	<b>(5,365,650)</b>	<b>(4,181,812)</b>
Balance for common	(5,804,486)	(4,595,276)
Earnings common share		
Primary	\$(0.22)	\$(0.23)
Fully Diluted	\$(0.22)	\$(0.23)
Common Shares:		
Full Diluted	26,296,188	19,714,396
Year-end	27,307,455	20,293,173

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	36,067,880
Inventories	4,276,330
Current assets	42,034,187
Net property & equip.	4,178,799
Total assets	47,766,398
Liabilities:	
Current liabilities	3,181,536
Stockholders' equity	44,584,862
Net current assets	38,852,651

**WALKER INNOVATION INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	656,000	1,284,000
Operating income	(656,000)	(1,284,000)
Interest income	41,000	4,000
Other income (expense), net		120,000
<b>Net income</b>	<b>(615,000)</b>	<b>(1,160,000)</b>
Earnings common share		
Primary	\$(0.03)	\$(0.06)
Fully Diluted	\$(0.03)	\$(0.06)
Common Shares:		
Full Diluted	20,094,000	20,742,000
Year-end	20,094,314	20,741,572

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	3,313,000
Current assets	23,405,000
Total assets	23,405,000
Liabilities:	
Current liabilities	200,000
Stockholders' equity	23,205,000
Net current assets	23,205,000

**WHERE FOOD COMES FROM INC**

**Resignation of Accountant** On May 21, 2018, EKS&H, LLLP resigned as Co.'s independent public accounting firm.

**WOODSTOCK HOLDINGS INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	1,763,471	1,635,881
Cost & expenses	1,816,621	1,668,487
<b>Net income</b>	<b>(53,150)</b>	<b>(32,606)</b>
Earnings common share		
Primary	\$(0.04)	\$(0.03)
Fully Diluted	\$(0.04)	\$(0.03)
Common Shares:		
Full Diluted	2,031,588	1,953,853
Year-end	2,141,862	1,953,858

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	406,164
Current assets	744,511
Net property & equip.	870,262
Total assets	1,856,744
Liabilities:	
Current liabilities	330,809
Long-term debt	768,149
Stockholders' equity	691,118
Net current assets	413,702

**WORKHORSE GROUP INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	560,229	1,570,037
Cost & expenses	6,452,148	9,454,992
Interest expense	525,887	35,651
<b>Net income</b>	<b>(6,417,806)</b>	<b>(7,920,606)</b>
Earnings common share		
Primary	\$(0.16)	\$(0.24)
Fully Diluted	\$(0.16)	\$(0.24)
Common Shares:		
Full Diluted	40,258,234	32,965,419
Year-end	41,966,550	35,956,800

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	753,563
Inventories	5,027,569
Current assets	6,342,650
Net property & equip.	5,547,653
Total assets	12,122,003

Liabilities:	
Current liabilities	11,980,730
Long-term debt	1,700,608
Stockholders' equity	(1,559,335)
Net current assets	(5,638,080)

**WORLD TECHNOLOGY CORP****Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2017	2016
Total revenues	1,900,000	1,878,046
Cost & expenses	3,291,986	2,730,561
Operating income	(1,391,986)	(852,515)
<b>Net income</b>	<b>(1,350,872)</b>	<b>(852,515)</b>
Earnings common share		
Primary	\$(0.05)	\$(0.03)
Fully Diluted	\$(0.05)	\$(0.03)
Common Shares:		
Full Diluted	28,662,994	28,581,000
Year-end	28,662,994	

**WORLDNET INC OF NEVADA****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	5,600	5,600
Operating income	(5,600)	(5,600)
Net before taxes	(10,146)	(9,874)
<b>Net income</b>	<b>(10,146)</b>	<b>(9,874)</b>
Earnings common share		
Year-end	18,500,000	18,500,000

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	396
Current assets	396
Total assets	396
Liabilities:	
Current liabilities	315,469
Stockholders' equity	(315,073)
Net current assets	(315,073)

**YOSEN GROUP INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	67,420	61,580
Operating income	(67,420)	(61,580)
Other income (expense), net	(218)	(120)
Net before taxes	(67,638)	(61,700)
Income contin. oper.	(67,638)	(61,700)
<b>Net income</b>	<b>(219,672)</b>	<b>(349,789)</b>
Earnings common share		
Primary	\$(0.02)	\$(0.03)
Fully Diluted	\$(0.02)	\$(0.03)
Common Shares:		
Full Diluted	11,267,918	11,263,251
Year-end	11,267,918	

**Consolidated Balance Sheet Items, as of (\$):**

Assets:	2018
Cash & equivalents	31,727
Inventories	349,720
Current assets	953,472
Net property & equip.	147,319
Total assets	1,476,378
Liabilities:	
Current liabilities	5,300,960
Stockholders' equity	(3,718,162)
Net current assets	(4,347,488)

**ZAIS GROUP HOLDINGS INC**

**Merger Completed** On May 18, 2018, Co.'s wholly-owned subsidiary, ZGH Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Z Acquisition LLC ("Parent") of which Christian Zugel, Co.'s Chairman and Chief Investment Officer ("Mr. Zugel"), was the sole managing member. As the result of the merger, each share of Class A common stock of Co., par value \$0.0001 per share ("Class A Common Stock"), issued and outstanding immediately prior to the effective time of the Merger, other than (i) shares beneficially owned by Parent, Mr. Zugel, the members of Parent (including Mr. Zugel and Daniel Curry, Co.'s President and Chief Executive Officer), certain trusts for members of Mr. Zugel's family, and Mr. Zugel's spouse (collectively, the "Parent Group") and (ii) shares owned by holders who neither have voted in favor of the Merger nor consented thereto in writing and who have properly and validly

perfected, and not effectively withdrawn or lost their statutory appraisal rights under Delaware law (such shares of Class A Common Stock, "dissenting shares"), was converted into the right to receive \$4.10 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). In addition, each restricted stock unit in respect of shares of Class A Common Stock ("RSU") was converted into the right to receive the Merger Consideration multiplied by the number of shares underlying the RSU. The estimated total cost of completing the Merger, including payment of the aggregate Merger Consideration and related fees and expenses, was approximately \$33,500,000, which Co. funded or would pay from cash on hand, including \$12,649,676.70 that Co. received prior to the Merger from ZAIS Group Parent, LLC, Co.'s majority-owned subsidiary ("ZGP"), for the redemption of ZGP Class A Units ("Class A Units"). Prior to the redemption, Parent contributed 12,649,676.70 to ZGP in exchange for the issuance of 3,085,287 Class A Units by ZGP to Parent pursuant to the Investment Agreement, dated as of Jan. 11, 2018, entered into by ZGP, Parent and Mr. Zugel (solely in his capacity as the founder member representative of ZGP and solely with regard to consenting to the issuance of Class A Units pursuant to the Investment Agreement and cooperating with Co. to obtain any other consents).

**ZIX CORP****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	16,654,000	15,893,000
Cost & expenses	14,045,000	13,231,000
Operating income	2,609,000	2,662,000
Other income (expense), net	119,000	79,000
Net before taxes	2,728,000	2,741,000
Income taxes	836,000	966,000
<b>Net income</b>	<b>1,892,000</b>	<b>1,775,000</b>
Earnings common share		
Primary	\$0.04	\$0.03
Fully Diluted	\$0.04	\$0.03
Common Shares:		
Full Diluted	53,481,104	53,666,649
Year-end	54,251,627	54,398,490

**Consolidated Balance Sheet Items, as of (\$):**

	2018
Assets:	
Cash & equivalents	29,269,000
Current assets	33,051,000
Net property & equip.	3,843,000
Total assets	81,117,000
Liabilities:	
Current liabilities	31,609,000
Stockholders' equity	46,966,000
Net current assets	1,442,000

**ZYNEX INC****Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total revenues	6,876,000	3,436,000
Cost & expenses	4,921,000	2,953,000
Operating income	1,955,000	483,000
Net before taxes	1,840,000	362,000
Income taxes	(81,000)	9,000
<b>Net income</b>	<b>1,921,000</b>	<b>353,000</b>
Earnings common share		
Primary	\$0.06	\$0.01
Fully Diluted	\$0.06	\$0.01
Common Shares:		
Full Diluted	34,414,000	32,036,000
Year-end	32,606,743	32,048,484

**Consolidated Balance Sheet Items, as of (\$):**

	2018
Assets:	
Cash & equivalents	4,366,000
Inventories	710,000
Current assets	8,359,000
Net property & equip.	575,000
Total assets	9,309,000
Liabilities:	
Current liabilities	3,753,000
Stockholders' equity	5,304,000
Net current assets	4,606,000



\*

*MERGENT OTC UNLISTED News Reports 0895-3252* is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC UNLISTED Manual and provide periodic updates. Send address changes to MERGENT OTC UNLISTED, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2018 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.